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ABSTRACT
The metabolic syndrome (MS) has been linked to a significantly higher risk of 
heart disease and diabetes. It affects approximately 25% of Americans today with its 
prevalence continuing to increase as the population becomes heavier and more sedentary. 
With Pender’s Health Promotion model as a theoretical base, this study examined the 
prevalence of the risk factors, preventative and treatment measures for the metabolic 
syndrome among a Midwestern North American population. A non-experimental 
secondary data analysis comparative survey design approach was used through a chart 
review of 101 male patient charts and 101 female patient charts. Significance was 
established at p< .05.
Looking at the first of these risk factors it was found that 118, or 58.4% of the 
sample, had a diagnosis of hypertension while 33.7% (n=68) had a blood pressure 
reading over 130/85 mmHg. Of the 173 in the sample who had random glucose readings 
in their chart 16, six females and 10 males, had levels over 200 mg/dL. There were 78, 
43 males and 35 females, or 38.6% of the sample, who had diabetes. Altogether 88 men 
and 88 women had a body mass index (BMI) over 30 kg/m2 with the mean BMI of the 
sample being 38.1 kg/m2 (SD=7.6). Over half, 50.9%, of the sample with triglyceride 
readings had a level over 150 mg/dL. The mean triglyceride level was 206.4 mg/dL 
(SD=136.3). There were 12 females, out of a total of 21 with an high density lipoprotein 
(HDL) cholesterol level recorded, with an HDL level under 40 mg/dL and 32 males, out
xii
of 35 with an HDL level recorded, with a level under 50 mg/dL. The mean HDL level 
was 33.9 mg/dL (SD=12.3). Of the prevention and treatment measures studied several, 
such as the referrals for eye exams and to a dietician, were rarely found. Of those seen 
more often, the referrals for or foot examinations completed were seen in 55 charts, for 
30 male and 25 females. Of those with diabetes 34.6% had a foot examination or referral 
made. Of the medications or type of medication on which information was collected 
four, aspirin, diuretics, and statins, were used by approximately one third of patients. 
Angiotensin converting enzymes inhibitors were being taken by just under a fifth of the 
patients. There were 130, 67 males and 63 females, in the sample who had a record of an 
electrocardiogram completed.
As this study was retrospective using a chart review process, certain patients were 
not found to have all of the risk factors for the MS documented. Repeating the study with 
patients who had a record of each of these five risk factors would be beneficial as well as 
focusing more on the exact time when they were found to have these risk factors and 
what kinds of treatments were implemented. With the growing numbers of clients with 
the MS it is crucial that nurses be informed on current information on the MS so that they 




Metabolic syndrome (MS), also known as insulin resistance syndrome, the deadly 
quartet, the dysmetabolic syndrome, the cardiovascular dysmetabolic syndrome, or 
syndrome X, increases the risk of coronary heart disease (CHD) and diabetes (Ninomiya, 
L’ltalien, Criqui, Whyte, Gamst, & Chen, 2003). When the MS was first described in 
1956, abdominal obesity was seen as the main cause (Kutschman & Hadley, 2004). The 
most widely accepted definitions of the MS are the World Health Organization (WHO) 
and National Cholesterol Education Program’s (NCEP) (Kutschman & Hadley). In 2001 
the NCEP developed what is called the Adult Treatment Panel III (ATP III) guidelines 
for the diagnosis of the MS (Lawlor, Ebrahim, & Smith, 2004). According to this 
definition, MS exists if three of the following five symptoms are present: (a) high fasting 
glucose of over or equal to 110 mg/dL; (b) hypertension with a reading of 130/85 mmHg 
or higher; (c) raised plasma triglycerides of over or equal to 150 mg/dL; (d) low high 
density lipoprotein (HDL) cholesterol of under 40 mg/dL in women and 50 mg/dL in 
men; (e) central obesity with a waist circumference over 40 inches in men and over 35 
inches in women (National Institute of Health, 2002). Worldwide, the incidence of the 
MS is considered pandemic and in the United States (U.S.) the problem affects 22% of all 
adults (Kutschman & Hadley).
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Background and Significance
Working in a medical surgical unit in a rural hospital one sees many clients with 
diabetes and CHD who also have multiple risk factors for the MS. Rarely does one see 
the term metabolic syndrome used in patients’ charts. Considering the high likelihood of 
developing diabetes or coronary heart disease after developing metabolic syndrome, it 
would be important to identify those who have not gone on to develop these diseases and 
address the MS as soon as it is found. Looking at the prevalence of the MS and whether 
the MS has been addressed through preventative measures and treatments in this area 
would be important. This would be one step towards the more widespread use of the 
diagnosis to prevent diabetes, CHD and other diseases that often follow the MS.
It has been found that the MS presents differently in males and females (Novak, 
Stapleton, Litaker, & Lawson, 2003). Unfortunately, little research has been carried out 
to investigate how the prevalence of the risk factors, treatment, and prevention methods 
for MS differs between the genders. Little research has also been done studying the 
effect of age on the prevalence of the risk factors for the MS. This study addressed these 
factors in a Midwestern North American community.
Each of the five risk factors for the MS separately contributes to the risk for 
cardiovascular disease and having three or more of these risk factors greatly increases 
this risk (Costa, Canani, Lisboa, Tres, & Gross, 2004). Obesity and lack of exercise is 
epidemic today, leading to increased levels of the MS (Jorgensen, Bjerregaard, 
Gyntelberg, & Borch-Johnsen, 2004). Currently one in four Americans are at risk of 
developing the MS (Yoo, Nicklas, Baranowski, Zakeri, Yang, Srinivasan, & Berenson, 
2004). This problem is expected to escalate in the U.S. and abroad, with the prevalence
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of the MS estimated to be 50 to 75 million among U.S. adults by 2010. Considering this, 
studies are needed to determine the prevalence of the risk factors for the MS and the 
effectiveness of preventative measures and treatments that are being used today to 
combat MS (Kutschman & Hadley, 2004; Jorgensen et al., 2004).
Purpose
This study examined the prevalence of the risk factors, preventative and 
treatment measures for the MS in a Midwestern North American population.
Theoretical Framework
Pender’s Health Promotion Model (HPM) was used as a basis for this study. It is 
a midlevel model developed by Pender in 1982 to help nurses provide, “care that results 
in better health and more productive living for individuals and families” (Young, Taylor 
& Renpenning, 2001, p. 307). The focus of the model is on health rather than disease. 
Health is defined as more than simply the absence of disease. According to Pender it is 
the “actualization of inherent and acquired human potential” (Pender, 1990, p.l 16).
Pender’s HPM’s emphasis on health promoting practices and health promoting 
interventions are specifically relevant for this study as it seeks to determine the health 
promotion practices for those at risk for, or already diagnosed with, the MS. Primary 
care nurses promote an active lifestyle on every client visit (Pender, Murdaugh, &
Parsons, 2002). The American College of Sports Medicine recommends thirty minutes of 
moderate to intense physical activity most days of the week. Outcomes of this are 
improved circulatory status, endurance, better muscle function, and physical fitness. For 
children and adolescents, activities they enjoy and which can be continued into 
adulthood, should be encouraged. The nurse should assess the type and duration of
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exercise that adults participate in so they can help to develop a physical activity programs 
which are safe, enjoyable, convenient, realistic, and goal orientated. Regular monitoring 
and follow up is necessary in order for most clients to maintain these programs.
Becoming active ourselves as nurses is also key to being able to identify with and better 
communicate with clients about exercise.
Nurses can create opportunities to discuss nutrition on each primary care visit 
(Pender, Murdaugh, & Parsons, 2002). Besides engaging clients in a dialogue 
about nutrition, nurses also need to work with the community to improve food 
choices in cafeterias and vending machines. Knowing web sites which provide 
current nutrition information can be useful when providing education to clients. Again, 
role modeling weight management and good dietary habits ourselves is important.
The human capacity for self-directed change is stressed by Pender (Pender,
Murdaugh, & Parsons, 2002). She identifies the nurses' role as one of 
supporting a positive climate for change, acting as a catalyst for the change in 
health behavior and then acting to develop the patients' capacity to continue 
that change. In order to do this, the nurse must be sensitive to the client's 
culture, racial background and socioeconomic situation.
Developing cultural competence involves four steps. First, the nurse seeks to 
develop an awareness of differences between cultures; secondly, the nurse strives to 
attain cultural knowledge by understanding the values, beliefs, and lifeways of the other 
culture. Thirdly, the nurse becomes skilled at cultural assessment and culturally 
appropriate interventions; and lastly the nurse becomes immersed in the culture. The 
Midwestern community in which this study was carried out is becoming increasingly
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diverse. Matching the nurse and the client so that the nurse is culturally competent in 
terms of the client's culture will become more important with this change.
The HPM focuses on five areas, the first of which is the client's characteristics 
and experiences (Pender, Murdaugh, & Parsons, 2002). This includes the individual's 
prior related behavior and personal factors such as age, education, and self-motivation. 
The nurse will not be able to change some of these, but needs to take these into account 
when considering interventions focusing on the benefits of change and giving positive 
feedback.
Another of the five areas of the model is behavior specific cognition and 
affect (Pender, Murdaugh, & Parsons, 2002). This includes the six variables of 
perceived benefits of action, perceived barriers to action, perceived self-efficacy, activity 
related affect, interpersonal influences, and situational influences. The nurse needs to 
consider each of these areas and whether intervention is needed in order to work towards 
health promotion. The other three areas of the model consist of a commitment to a plan 
of action, immediate competing demands and preferences, and behavioral outcomes. The 
commitment to a specific plan of action involves having an action plan for a certain time 
and place. In addition there is also a specific strategy for carrying out this plan and then 
reinforcing the new behavior. Competing demands are those behaviors which the 
individual has low levels of control over as they are related to environmental factors such 
as work and family responsibilities. Competing preferences are those behaviors over 
which the individual has more control, such as dietary choices. Health promoting 
behavior is the desired outcome of the model. It aims to lead to improved health, greater 
functional ability, and a better quality of life.
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Research Questions
The following research questions were posed for the study:
1. How did the presence of the five risk factors, low HDL cholesterol, high 
fasting blood glucose, hypertension, high plasma triglycerides, and high body 
mass index (BMI) compare between the genders and age groups?
2. Was there a difference in the severity of the five risk factors, collected with 
the use of the adjusted diabetes chart audit form, between the genders and age 
groups?
3. Was there a difference between gender or age groups in terms of extent of 
preventative measures and treatment used for these risk factors?
Definitions
Several definitions for the metabolic syndrome have been put forward by various 
groups. The definition that will be used for this study, the ATP III definition, was 
developed by the NCEP Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults in 2001 (Lawlor, Ebrahim, & Smith, 2004).
1. Age Groups- The age categories of 21 -40, 41 -60, 61-80, and over 80 will be used 
in the analysis.
2. Metabolic Syndrome- According to the ATP III guidelines, metabolic syndrome 
exists if three or more of the following five symptoms are present: (a) high 
fasting glucose of over or equal to 110 mg/dL; (b) hypertension with a reading of 
130/85 mmHg or higher; (c) raised plasma triglycerides of over or equal to 150 
mg/dL: (d) low high density lipoprotein (HDL) cholesterol of under 40 mg/dL in 
women and 50 mg/dL in men; (e) central obesity with a waist circumference over
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40 inches in men and over 35 inches in women (National Institutes of Health, 
2002). For this study only the first four of these risk factors will be used, as waist 
circumference is rarely measured and recorded. Instead of the waist 
circumference measurement, a body mass index (BMI) of over or equal to 30 
kg/m will be used as described in the World Health Organization’s 1999 
definition of the MS (Novak, et al., 2003). As fasting blood sugar measurements 
were not found in many of the charts, a random blood sugar of 200 mg/dL or 
greater or a diagnosis of diabetes was used instead.
3. Preventative Measures- Any therapy or recommendations such as dietary or 
exercise counseling that would help to reduce the risk of the MS. The extent of 
the preventative measures will be determined by the number of measures carried 
out.
4. Severity- The severity of risk factors for the MS will be determined by the amount 
they are over the levels described by the ATP-III definition. Triglycerides will be 
defined according to the ATP-III definition with high defined as 150-499 mg/dL 
and very high as over or equal to 500 mg/dL (National Institutes of Health, 2002). 
Hypertension will be defined according to the Joint National Committee, a group 
set up by the National Institutes of Health (National Institutes of Health, 2003). 
They defined stage one hypertension as 140-159/90-99 mmHg, and stage two 
hypertension as over or equal to 160 mmHg systolic and over and equal to 100 
mmHg diastolic. The definition given by the National Institutes of Health will be 
used for determining the severity of the BMI risk factor. It categorizes class one 
obesity as a BMI of 30 kg/m2 to 34.9 kg/m2, class two obesity as a BMI of 35
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kg/m2 to 39.9 kg/m2 and class three obesity as a BMI of over or equal to 40 kg/m2 
(National Institutes of Health, 2000). No inverse relationship has been found 
between HDL cholesterol and coronary heart disease and therefore any 
categorization of it is arbitrary (National Institutes of Health, 2002). For the 
purpose of this study, however, the categories under 30 mg/dL and 30 mg/dL to 
40 mg/dL will be used for women and under 40 mg/dL and 40 mg/dL to 50 
mg/dL will be used for men. No categorization could be found for hyperglycemia 
therefore an arbitrary categorization of 200 mg/dL to 249 mg/dL, 250 mg/dL to 
299 mg/dL, 300 mg/dL to 349 mg/dL, and 350 mg/dL to 399 mg/dL will be used.
5. Treatment- Any measures taken after a diagnosis of MS (whether in the chart or 
determined through the ATP-III guidelines by the researcher) that are directed at 
reducing or eliminating the risk factors for the MS. The extent of treatment will 
be determined by the number of measures carried out.
Limitations and Assumptions 
The following limitations applied to this study:
1. By not having a record of waist hip circumference, the ATP-III definition had to 
be modified with BMI being used as a risk factor instead. Random blood glucose 
readings were used as a risk factor as fasting blood glucose measurements were 
also rarely seen.
2. Collecting data for the study at a hospital led to a bias in the resulting data as the 
clients were not representative of the general population.
3. The small sample number included in the study limited generalization to the 
broader population.
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4. In many cases one or more of the risk factor data, treatment or prevention 
initiatives were missing in the charts reviewed.
5. In some cases it was difficult to distinguish whether treatments started were 
initiated specifically to address the risk factors for the MS or for another 
condition.
6. Certain drugs, such as Aspirin, may not be appropriate for certain patients. Not 
knowing this during the chart review and analysis may bias the results as it may 
be expected that they receive this treatment.
The following assumptions applied to this study:
1. The charts reviewed had the necessary data to determine whether the client has 
risk factors for the MS and has had prevention and treatment measures initiated.
2. Another assumption was that knowing the ways in which risk factors, prevention, 
and treatment differ between the genders and age groups was essential in 
preventing the MS.
The MS is becoming a greater problem in the U. S. and abroad with the rising 
levels of obesity and inactivity worldwide. Taking steps to prevent the MS before 
diseases such as diabetes and cardiovascular disease develop, and treating the MS once it 
is diagnosed, is necessary for health care providers. To do this, research is needed to 
determine the incidence of the MS in this area as well as information on what is being 
done in terms of prevention and treatment.
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CHAPTER II
REVIEW AND CRITIQUE OF RELATED LITERATURE 
The definition of the MS has changed over time with the most recent definitions 
including the five risk factors: (a) high fasting glucose; (b) hypertension; (c) low high 
density lipoprotein; (d) central obesity. The first four of these five risk factors will be 
used in this study. Other risk factors that have been thought to contribute to this 
syndrome include abnormalities of uric acid, inflammation, hemostasis, fibrinolysis, and 
brachial-ankle pulse wave velocity (Ford, Mokdad, Giles, & Brown, 2003; Choi, Lee, 
Seo, Oh, Kim, Kim, Choi, Baik, 2004). In this section the literature related to high 
fasting glucose, hypertension, raised plasma triglycerides, low high density lipoprotein 
cholesterol, and obesity will be examined. The literature on preventative measures and 
treatment recommendations made for those with the MS, and nursing implications for 
those working with clients diagnosed with this syndrome will then be addressed.
High Fasting Glucose
Up to 25% of adults in the U.S. have some degree of insulin resistance, a 
condition associated with high fasting glucose (Kutschman & Hadley, 2004). In the U.S., 
7% of the population has been found to have a fasting glucose of 6.1 mmol/1 to 6.9 
mmol/1 (Jacobson et al., 2004). Individuals with high fasting glucose levels are at risk of 
the MS and cardiovascular disease. Those with impaired fasting glucose levels or 
impaired glucose tolerance also have one-and-a-half times the risk of cardiovascular 
disease compared to those with normal blood glucose levels (Kutschman & Hadley). A
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retrospective study, done in Goteborg, Sweden, with 284 middle-aged Caucasian males 
used EQS Multivariate Software Version 5.7b for their statistical analysis and found 80% 
of men with insulin resistance have the MS when adiposity is defined by the WHO 
criteria (Novak, et al., 2003). Another cross-sectional study (Lawlor et al., 2004) of 
3,770 women aged 60-79 years, conducted in Britain, using multiple logistic regression 
to analyze the statistics, determined that insulin resistance alone, hypertension alone, and 
dyslipidemia alone were all associated with CHD at a similar level as the MS. Low high 
density lipoprotein (HDL) was found to have the highest association with the MS and 
overall the ATP-II defined syndrome was found to have an 11 % risk for CHD (Lawlor et 
al.).
Some have questioned the accuracy of using fasting blood glucose as part of the 
definition for the MS, pointing out that this method may miss many with impaired 
glucose tolerance and diabetes (Jorgensen et al., 2004). Jorgensen et al. suggest using 2-h 
plasma glucose levels instead as this has been found to have a higher association with 
insulin sensitivity, insulin resistance, and cardiovascular disease. Other studies have 
looked at how the MS relates to complications of diabetes and antioxidants. A cross- 
sectional study conducted with 548 patients with Type 2 diabetes mellitus, using multiple 
logistic regression analyses, looked at the complications of diabetes and risk factors for 
the MS. The study found 85% of the sample had the MS and that this diagnosis was 
associated with a linear increase in the proportion of diabetic complications including 
retinopathy and peripheral neuropathy (Costa et al., 2004). Antioxidant levels have also 
been found to be inversely related to insulin resistance in a number of studies
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(Ford, et al., 2003). This relationship, however, remains uncertain as several other 
studies failed to show this relationship (Ford et al.).
Insulin resistance has been found to have a genetic component. A study done 
with 27 Mexican-American families in Texas, that tested the sample for the five risk 
factors for the MS, found a link between chromosomes 6 and 7 and insulin resistance 
syndrome (Arya, Blangero, William, Almasy, Dyer, Leach, O’Connell, Stem, & 
Duggirala, 2002). Another study found almost half, 45%, of nondiabetic individuals with 
a first-degree relative with type 2 diabetes are insulin resistant themselves, compared to 
just 20% of nondiabetic individuals with no family history of insulin resistance (Arya et 
al., 2002).
Hypertension
In the United States, 24% of the population have blood pressure readings over or 
equal to 140/90 mmHg (Jacobson, Case, Roberts, Buckley, Murtaugh, Sung, Gause, 
Varas, & Ballantyne, 2004). Although one in four U.S. adults has hypertension, only two 
thirds of these patients have been diagnosed (Kutschman & Hadley, 2004).
Some studies have found that individuals with hypertension tend to have insulin 
resistance as well: about half of those with hypertension are found to have insulin 
resistance and hyperinsulinemia (Florez et al., 2005). Some, but not all, studies have 
found a significant correlation between fasting insulin and blood pressure (Florez, et al., 
2005).
A study conducted with 4,549 members of several American Indian tribes across 
the U. S. examined those in the sample to determine their medical history, brachial and 
ankle blood pressure, fasting glucose, glycosylated hemoglobin, lipid and lipoprotein
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levels, 2 hour glucose tolerance, low density lipoprotein (LDL), very LDL, and HDL 
levels among other measures to determine how cardiac structure and function compared 
to those with the MS. The researchers found abnormal left ventricular geometry and 
function were related to the MS and particularly with the risk factor of hypertension 
(Chinali, Devereux, Howard, Roman, Bella, Liu, Resnick, Lee, Best & Simone, 2004). 
Left ventricular changes included hypertrophy, impaired chamber and wall mechanics, 
and abnormal early diastolic relaxation (Chinali et al., 2004).
Another retrospective study looked at clinical and biochemical data such as blood 
pressure and total serum cholesterol to find the variation of the prevalence of the MS 
among various age groups in patients with Type 2 diabetes. The authors found women 
had a higher prevalence of hypertension (p>0.1) and adiposity (p>0.1) than males, while 
males had higher uric acid (p<0.01) and lower HDL levels (p>0.1) (Relimpio, Marinez- 
Brocca, Leal-Cerro, Losada, Mangas, Pumar, & Asorga, 2004). The higher adiposity and 
increased prevalence of hypertension in women was found to be counterbalanced in 
males by the lower HDL levels. The MS associated risk was not found to differ 
significantly between premenopausal, perimenaupausal, and postmenopausal women.
Raised Plasma Triglycerides
Elevated serum triglycerides have been positively associated with CHD 
(Kutschman & Hadley, 2004). Many factors including obesity, physical inactivity, 
cigarette smoking, excessive alcohol intake, high carbohydrate diets, comorbid disease, 
medication, and genetic disorder have been found to lead to elevated triglycerides 
(Kutschman & Hadley). The authors of a cross-sectional retrospective study of 10,357 
adult subjects, looked at insulin resistance, hypertension, hypertriglyceridemia, low HDL
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cholesterol, and abdominal obesity. They found all the risk factors associated with the 
MS, except high waist circumference, were significantly associated with self-reported 
myocardial infarction and stroke (Ninomiya et ah, 2003). Overall, hypertriglyceride 
levels were found to have the strongest relationship of the five ATP-III defined risk 
factors for the MS (Ninomiya et al.). The literature related to the MS and specifically the 
risk factor of high triglycerides has brought up the question of whether two measures of 
dyslipidemia are needed in the definition of the MS. They point out that they probably 
do not contribute equal disease risk and may overemphasize the impact of elevated 
tryglycerides and cholesterol levels (Jorgensen et al., 2004).
Low High Density Lipoprotein Cholesterol
The ATP-III definition includes a low high density lipoprotein (HDL) cholesterol 
level of under 1.0 mmol/1 as one of the risk factors for the MS. In the U.S. approximately 
33% of men and 20% of women have a high density lipoprotein cholesterol level (HDL- 
C) under 1.03 mmol/1 (40 mg/dL) (Jacobson et al., 2004). Among the risk factors for the 
MS high triglyceride, low HDL-C levels and elevated blood pressure are found more 
frequently than elevated glucose (Jacobson et al.).
A prospective study involving 3,033 participants, age 70-79 years, in the Eastern 
U.S. looked at the association between the MS, circulating oxidized LDL, and the risk of 
myocardial infarction. They used the ATP-III guidelines to identify MS prevalence and 
cardiac procedures and diagnoses reported to the U. S. Department of Health and Human 
Services Centers for Medicare and Medicaid Services over the previous five years. 
Findings that were reported included that those with the MS have higher levels of 
oxidized LDL. This applied to both genders and among various ethnic groups
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(Holvoet, Kritchevsky, Tracy, Mertens, Rubin, Butler, Goodpaster, & Harris, 2004). 
Oxidized LDL was found to be associated with the plasma glucose levels and CHD, 
while HDL was been found to have an inverse relationship with oxidized LDL (Holvoet 
et ah, 2004).
The authors of another study that used questionnaires, laboratory data and 
assessments to collect information on the MS and dyslipidemia among 3,108 adults in 
various ethnic groups in Venezuela found the prevalence for the MS and dyslipidemia 
was 31% and 24% respectively (Florez, Silva, Fernandez, Ryder, Sulbaran, Campos, 
Calmon, Clavel, Castillo-Florez, & Goldberg, 2005). The U.S. rates for the MS among 
men was 24%, significantly lower than the Venezuelan rate of 35%. The U.S. female 
rates were also lower at 23% compared to the Venezuelan rate of 30% (Florez et al., 
2005). Low HDL and abdominal obesity was found most frequently in those with the 
MS who had a sedentary lifestyle (Florez et ah). Other interesting findings of this study 
included the variable MS prevalence rate among age and BMI groups and the similar 
prevalence among women but varied prevalence among men (Florez et ah). Men had 
higher levels of dyslipidemia and blood pressure and overall MS prevalence, while the 
sample as a whole had a one in four incidence of dyslipidemia (Florez et ah). Family 
history of obesity, diabetes and sedentary lifestyle were found to be linked to the MS and 
dyslipidemia, but affected the various ethnic groups and gender differently (Florez et ah).
Obesity
In the United States, 97 million adults are obese and over half of the population 
are overweight (Kutschman & Hadley, 2004). Android pattern obesity, or upper body 
obesity, has been found to be more frequently associated with diabetes and CHD than
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other types of obesity (Kutschman & Hadley). Abdominal fat particularly has been found 
to be an independent predictor of diabetes and CHD, even when BMI numbers are not 
elevated (Kutschman & Hadley). Park and Lee (2004) reported abdominal fat and 
visceral fat associated with insulin resistance and cardiovascular disease risk at any BMI 
level. Visceral fat reduction has been found to be especially beneficial for clients with 
the MS as it improves plasma glucose and lipid metabolism (Park & Lee, 2004). In their 
longitudinal 12 week intervention study Park and Lee studied 85 subjects who 
participated in a weight reduction program and then had their visceral, subcutaneous, and 
total adipose tissue levels determined by computer tomography scan. The authors 
reported those with visceral obesity, compared to those with subcutaneous obesity, 
experienced the greater benefits in terms of insulin resistance. Changes in visceral or 
subcutaneous adipose tissue did not, however, impact blood pressure or HDL cholesterol 
(Park & Lee).
Obesity is associated with decreased concentrations of antioxidants, which in turn 
may play a role in the development of diabetes and cardiovascular disease (Ford et al., 
2003). The Third National Health and Nutrition Examination Survey studied a 
representative sample of noninstitutionalized civilians, using the ATP-III guideline 
definition for the MS testing their serum levels of retinol and retinyl esters, vitamin E, 
and fiber carotenoids. The authors found those with the MS consume fewer fruits and 
vegetables (p= 0.024) suggesting they have a lower antioxidant intake (Ford et al.).
Those with the MS, for example, were found to have 40% lower levels of vitamin C 
concentrations and 27% lower total carotenoid concentrations than those without the MS.
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The authors also suggested those with the MS have an increased rate of use of 
antioxidants possibly as a result of the oxidative stress they are undergoing (Ford et al.).
Yoo et al. (2004) did a cross-sectional study of 1,420 young adult participants in 
Los Angeles, looking at dietary intake in the relation to the MS. They found those who 
had no risk factors for the MS consumed more alcohol, low-fat dairy products, fruit, fruit 
juice, vegetables, diet beverages and less sweetened beverages than those with risk 
factors for the MS. They also found a moderate consumption of alcohol increased the 
concentrations of circulating HDL and appeared to reduce platelet aggregation, working 
similarly to aspirin (Yoo et al.; Lee, Jung, Park, Rhee, & Kim, 2005). They warned that 
alcohol is a significant risk factor for the development of hypertension (Yoo et al., 2004). 
Fruit was thought to possibly have an antiobesity effect through intracellular calcium and 
other bioactive compounds (Yoo et al.). Fruit and vegetables high in fiber, antioxidants, 
and vitamins were found to improve glucose control and peripheral insulin sensibility and 
reduce impaired glucose tolerance and cardiovascular diseases (Yoo et al.). Exercise has 
also been found to increase insulin sensitivity (Lee et al.). Yoo et al. also found that a 
higher consumption of sweetened beverages has been associated with overweight status 
especially in children and adolescents. Those who were overweight tended to have more 
insulin resistance and be more susceptible to lifestyle effects (Yoo et al.).
In the U.S., over 60% of women are overweight (Kip, Marroquin, Kelley, 
Johnson, Kelsey, Shaw, Rogers, & Reis, 2004). The prevalence of obesity has also 
doubled in the last decade, increasing from 15% to 30% (Kip et al., 2004). Kip et al., in 
their study of 780 women in the U.S. found the MS, but not body mass index, predicts 
future cardiovascular risk in women (Kip et al.). They pointed out that obesity and the
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MS do not necessarily always go together, with the MS also being present in lean 
individuals (Kip et al.). Inflammation was also mentioned in this article as being part of 
the MS and associated with cardiovascular risk (Kip et al.). Subclinical inflammation can 
be measured by testing high sensitivity-C-reactive protein levels (Kip et al.).
Preventative Measures and Treatment Recommendations
With the metabolic syndrome increasing the risk of coronary heart disease by as 
much as six times, aggressive therapy is recommended (Jacobson et al., 2004). First line 
therapy in most cases is lifestyle changes including changes in diet and exercise patterns 
(Jacobson et al.; Novak, et al., 2003; Linfeldt et al., 2003). Even a moderate weight loss 
of 6.5% can have a major impact, resulting in an 11 mmHg reduction in systolic and a 6 
mmHg reduction in diastolic blood pressure, 17 mg/dL reduction in glucose and a 37 
mg/dL reduction in total cholesterol level (Case, Jones, Nelson, Smith & Ballantyne, 
2002). The majority of those who continue to lose weight continue to have reductions in 
these levels until they no longer have the risk factors for the MS. For those who are 
unable to make the necessary lifestyle changes, pharmacologic interventions such as 
antihypertensive, antidiabetic and lipid-regulation medications, may be needed (Jacobson 
et al.). Although some may require this type of intervention most, 60%, do not need 
pharmacologic interventions according to the ATP-III guidelines (Jacobson et al.).
Only a small percentage of those with the MS have substantially elevated LDL 
cholesterol that warrants drug therapy (Jacobson et al., 2004). However, with those 
having high triglyceride levels and/or with low HDL-C levels, statins or fibrates are 
recommended (Jacobson et al.). Those at a high cardiovascular risk are also advised to set 
a goal of 100 mg/dL for their LDL (Meyers, Johnson, Klardie, & McNaughton, 2004). A
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combination of simvastatin and niacin has been shown to decrease the risk of CHD by 
90% in those with the MS (Jacobson et al.). Further studies are needed to determine if 
the benefits of these drugs outweigh the risks in those with the MS (Jacobson et al.).
The goal for those with hypertension is to reduce their level to below 130/80 
mmHg (Kutschman & Hadley, 2004). To begin, clients are encouraged to change their 
lifestyle by reducing their weight, their alcohol intake, increasing their physical activity 
level, stopping smoking, and reducing their intake of saturated fats, cholesterol and 
sodium (Kutschman & Hadley). Diet modification alone has been found to decrease 
blood pressure while exercise alone increases HDL cholesterol (Park & Lee, 2004). 
Aspirin is also recommended as a preventative measure for those with CHD to help 
reduce the risk of thrombosis (National Cholesterol Education Program, 2001). If these 
measures fail or if other factors, such as the presence of target organ damage indicate, 
antihypertensives can be used (Kutschman & Hadley). A long-acting dose given once a 
day is recommended to reduce side effects and increase patient adherence (Kutschman & 
Hadley).
To reduce high fasting blood glucose levels, changes in diet and exercise are 
again recommended. Thirty minutes of moderate physical activity along with a 5% to 
10% decrease in body weight have been found to lead to a 58% decrease in the risk of 
developing diabetes (Kutschman & Hadley, 2004). Most non-diabetics with the MS are 
not recommended for drug therapy (Jacobson et al., 2004).
Nursing Implications
Intervention in the form of education, and in some cases pharmacological 
treatment, is key to preventing diseases such as diabetes among those with the MS
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(Case et al., 2002). Kutschman and Hadley (2004) stress how the MS is now one of the 
most prevalent diseases but also one of the most preventable. A multidisciplinary 
approach to the MS that stresses dietary instruction, exercise, and behavioral 
modification has been found to be effective (Case et al.). Setting goals, such as losing 
10% of body weight over the first six months, with a one to two pound decrease each 
week is recommended. Other interventions, such as encouraging clients to consume diets 
high in antioxidants containing fruits and vegetables, are also important. If clients are not 
obtaining enough vitamins A, C, and E through their diet, having them take the 
appropriate vitamin supplements would be important considering the association of 
antioxidants with the MS (Ford et al., 2003). Focusing on elevated glucose and lipid 
abnormalities, which have been found to be the most important of the five ATP-III 
criteria, is also important for health care providers working with those who have the MS 
(Kutschman & Hadley).
Along with the physical symptoms and laboratory tests, nursing needs also to 
focus on the socio-demographic and psychosocial aspects related to the MS, when 
involved in primary prevention of the condition. A cross-sectional prospective study of 
10,766 Caucasian women aged 50-59 years in southern Sweden was done to study these 
aspects (Lidfeldt, Nyberg, Nerbrand, Samsioe, Schersten, & Agardh, 2003). Biological 
and socio-demographic information was collected, as well as physical activity levels, 
dietary habits, aspects of quality of life, and subjective physical and mental symptom 
information. The study found a reduced risk of the MS in women who had a healthy life 
style (p>0.001) with high intensity leisure time exercise (p<0.001), healthy dietary habits, 
low consumption of alcohol (p<0.001), and higher levels of education (p<0.001)
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(Lidfeldt et al., 2003). Other studies have found social inequality, social isolation, and 
psychological stress are also associated with the MS (Lidfeldt et al.). Similarly, Lee et al. 
(2005) found those with a low education level had a 6.3 risk of developing the MS 
(p<0.001) and those with a family history of the MS had a risk of 1.5 (p< 0.05) of 
developing the syndrome. Adapting the interventions to the client’s specific 
circumstances is crucial in helping them to change their lifestyle when they already are 
fully informed of the significant benefits of the necessary life style changes (Lidfeldt et 
al.).
The five risk factors for the MS are commonly seen, in the U.S. and abroad. High 
fasting glucose, for example, is present in 25% of adults in the U.S., hypertension in 24% 
of the U. S. population, and obesity in 97 million adults in the U.S. (Kutschman & 
Hadley, 2004; Jacobson et al., 2004). Most of the risk factors for the MS have been 
found to be linked to lifestyle patterns and some, such as high fasting glucose, to 
genetics. Lifestyle changes are recommended as first line treatment for the MS. If this is 
not effective medications may be used to control the symptoms of the syndrome. Thus 
nurses working with clients, to prevent or treat the need to focus on education concerning 
lifestyle changes needed, in terms of diet and exercise. Each client’s specific 
circumstances need to be taken into consideration when developing intervention plans 





Evidenced based practice is crucial when caring for patients, including those with 
the metabolic syndrome (MS). With a push for evidenced practice health care 
professionals are required to have increased accountability both fiscally and clinically 
(Goolsby, 2004). To do this, research is needed to provide the information on which to 
base rationale on for these care practices. Although research has been carried out on the 
MS for several decades much remains to be done in this area. This research study 
addressed one of these areas by exploring the prevalence of risk factors, as well as 
preventative and treatment measures for the MS in a Midwestern North American 
population. The following describes the population and sample that was studied in this 
research project. The study design is described along with the data collection methods 
and procedures. Also included are the reliability and validity of the instruments used. 
Finally, the data analysis plan and methods used to protect those studied are described.
Population
The target population consisted of all Midwestern North Americans over the age 
of 21 who were admitted to a rural Minnesota hospital. Convenience sampling was used 
to determine those in the sample. Those most recently admitted were included in the 
study as this provided the most current information.
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Sample
A total of 202 individuals (101 females and 101 males) age 21 and older were 
selected via convenience sampling. All subjects had been diagnosed with obesity 
between 2002 to 2005, according to medical records from a Midwestern health center. 
Subjects may or may not have presented with any of the following risk factors for the 
MS: high fasting glucose 110 mg/dL or greater, hypertension with a reading of 130/85 
mmHg or higher, raised plasma triglycerides 150 mg/dL or greater, low high density 
lipoprotein (HDL) cholesterol of under 40 mg/dL in women or 50 mg/dL in men, central 
obesity with a waist circumference over 40 inches in men or over 35 inches in women.
Design
A non-experimental secondary data analysis comparative survey design approach 
was utilized. Limitations to a comparative design include the problems of equivalence of 
concepts, with certain ideas and words meaning different things to people in different 
cultures. Although this was not a survey or questionnaire based study, the charts 
reviewed may have contained information that reflects this limitation. With the survey 
approach, another limitation is the difficulty of making clear causal inferences from 
information collected.
Data Collection Methods and Procedures 
The administration at the local hospital was contacted about the possibility of 
conducting the study at their facility. Once approval was granted, the medical records 
department was contacted and times were scheduled for reviewing medical record. A 
brief verbal report of the study protocol was provided to the hospital administration and 
the medical records contact person. A written description of the study was also provided
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to the facility. The medical records were reviewed in a location where confidentiality of 
the patient information was maintained. Data collection occurred during the winter of 
2005.
Instrument Reliability and Validity
An instrument called the Migrant Health Service, Inc. Diabetes Chart Audit 2003 
was revised and used to evaluate for the risk factors, prevention methods and treatment 
for the MS. This tool addresses the co-morbid diseases, lab values, height, weight, home 
medications, referrals, current care services provided, and present health habits. Changes 
were made to this tool so that it focused less on diabetes, by eliminating some of the more 
specific sections dealing with foot care and insulin. The focus of the tool was on MS 
prevention and treatment, including diet, exercise, and medication to reduce 
hypertension, high plasma triglyceride levels, and elevated glucose levels (Appendix A).
The tool’s face validity was tested by giving it to an expert panel of two faculty 
and two health care providers knowledgeable on the subject. Content validity was tested 
through the literature review by comparing risk factors, prevention methods, and 
treatments mentioned there with those in the instrument.
Data Analysis Plan
Data analysis included t-tests, chi-square tests, and Pearson’s product moment 
correlation as required according to the type of data (nominal, interval, or ratio). 
Significance was determined according to an alpha level of 0.05.
Protection of Human Subjects
Approval was obtained from the University of North Dakota Institutional Review 
Board, as well as from the administration of the hospital where the study was conducted.
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All data collected was kept under lock or with the protection of a password in a computer 
during the course of the study in order to ensure the confidentiality of those included. 
After the study is complete the data was destroyed. No names or other identifiers were 





The purpose of this study was to examine the prevalence of the risk factors, as 
well as preventative and treatment measures for the metabolic syndrome (MS) in a 
Midwestern North American population. The following research questions were posed 
for the study:
1. How did the presence of the five risk factors, low HDL cholesterol, high 
blood fasting glucose, hypertension, high plasma triglycerides, and high BMI 
compare between the genders and age groups?
2. Was there a difference in the severity of the five risk factors, collected with 
the use of the adjusted diabetes chart audit form, between the genders and age 
groups?
3. Was there a difference between genders or age groups in terms of extent of 
preventative measures and treatments used for these risk factors?
In this chapter the main characteristics of the sample are described, followed by 
an analysis of the data collected as it relates to each of the three research questions.
Sample Characteristics
A total of 202 charts were reviewed for the study, 101 charts of male patients and 
101 of female patients. The charts chosen were from the most recent visits of clients, age 
21 or older, who had a past diagnosis of obesity. Each of the patients had a health care
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visit at the medical facility within the last two years, 2004 and 2005. Over half of the 
sample, 55.4%, had a patient visit in the facility during 2005. As shown in Table 1 the 
age of those in the sample ranged from 21 to 100 with 17.3% (n=35) being age 20 to 40, 
43.1% (n=87) age 41 to 60, 35.6% (n=73) age 61 to 80, and 4% (n=8) age 81 and older. 
The majority of both males and females were between the age of 41 and 80. In the 41 to 
60 age group there were 37 males and 50 females, whereas in the 61 to 80 age group 
there were 38 females and 34 males. In the younger age bracket of 20 to 40, there were 
22 females and just 13 males. In the oldest age group of 81 to 100, there were 4 females 
and 4 males.
Table 1. Breakdown of Sample in Terms of Age and Gender
Age Group Female Male Total
20-40 Count 22 13 35
Expected Count 17.5 17.5 35.0
% within Age Group 62.9 % 37.1% 100.0%
% within Gender 21.8% 12.9% 17.3%
% within Total 10.9% 6.4% 17.3%
41-60 Count 37 50 87
Expected Count 43.5 43.5 87.0
% within Age Group 42.5% 57.5% 100.0%
% within Gender 36.6% 49.5% 43.1%
% within Total 18.3% 24.8% 43.1%
61-80 Count 38 34 72
Expected Count 36.0 36.0 72.0
% within Age Group 52.8% 47.2% 100.0%
% within Gender 37.6% 33.7% 35.6%
% within Total 18.8% 16.8% 35.6%
81-100 Count 4 4 8
Expected Count 4.0 4.0 8.0
% within Age Group 50.0% 50.0% 100.0%
% within Gender 4.0% 4.0% 4.0%
% within Total 2.0% 2.0% 4.0%
Total Count 101 101 202
Expected Count 101.0 101.0 202.0
% within Age Group 50.% 50.0% 100.0%
% within Gender 100.0% 100.0% 100.0%
% within Total 50.0% 50.0% 100.0%
Note: A Pearson Chi-Square value of 4.47, df value of 3, g value of .21, and a Pearson R 
t value of .45 was found when this data was analyzed.
Just 2% of the sample had a diagnosis of obesity in their chart. Table 2 shows
how the range of the body mass index (BMI) varied from 20.3 kg/m2 to 68.6 kg/m2 with a
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mean of 38.1 kg/m (SD=7.6). Of the charts reviewed, 12 did not have adequate 
information to calculate the BMI. Of the total sample, 7.4% (n=l 5) had a BMI of 20 
kg/m2 to 29.9 kg/m2, 24.8% (n=50) had a BMI of 30 kg/m2 to 34.9 kg/m2, 27.7% (n=56) 
had a BMI of 35 kg/m2 to 39.9 kg/m2, and 34.2% (n=69) had a BMI of over 40 kg/m2. 






BMI Class 0 (20 to 29.9) 15 7.4 7.9 7.9
GrouP Class 1 (30 to 34.9) 50 24.8 26.3 34.2
Class 2 (25 to 39.9) 56 27.7 29.5 63.7
Class 3 (40 or over) 69 34.2 36.3 100.0
Total 190 94.1 100.0
Missing System 12 5.9
Total 202 100.0
Eight charts were found to have the hemoglobin AIC levels, which is a measure 
of blood glucose over the last five to six weeks. These values ranged from 5.0% to 
11.7% with the mean of 7.8% (SD=2.0). Two charts contained fasting blood glucose 
levels. These values were 103 mg/dL and 107 mg/dL. The 173 random glucose levels 
collected from the charts ranged in value from 64 mg/dL to 351 mg/dL with the mean of 
129 mg/dL (SD=48). There were 16 values over 200 with 68.9% (n=l 1) of these 
between 200 and 249, 18.8% (n=3) between 250 and 299 and the other 12.6% (n=2) over 
300. Two charts contained records of the patient doing home blood glucose monitoring, 
although 78 (38.6%), of the patients were recorded as having diabetes (Table 3).
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Dx No 124 61.4 61.4 61.4
of Yes 78 38.6 38.6 100.0
DM Total 202 100.0 100.0
As seen in Table 4, of the total sample 118 (58.4%) were found to have a 
diagnosis of hypertension. Blood pressure readings were found in 200 of the charts 
reviewed. Among these 200, 65.3% (n=132) had readings under 130/85 mmHg while the 
other 33.7% (n=68) had readings over this level, with 33 having readings over 160/100 
mmHg (Table 5).






Dx of No 132 65.3 66.0 66.0
HTN Yes 68 33.7 34.0 100.0
Total 200 99.0 100.0
Missing System 2 1.0
Total 202 100.0






No 132 65.3 66.0 66.0
Yes 68 33.7 34.0 100.0
Total 200 99.0 100.0
Missing System 2 1.0
Total 202 100.0
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Liver and kidney function was assessed by collecting data on creatinine, 
microalbumin, and alanine transaminase (ALT) levels. Creatinine levels were present in 
172 charts with levels ranging from 0.4 mg/dL to 9.8 mg/dL with a mean level of 1.2 
mg/dL (SD=1.2). Only one chart contained information on the microalbumin level, in 
this case 5.4 mg/day. ALT levels were documented in 90 of the charts. Levels ranged 
from 10 U/L to 583 U/L with a mean of 61.2 U/L (SD=76.3).
Total cholesterol values were recorded in 56 of the charts reviewed. Levels 
ranged from 98 mg/dL to 284 mg/dL with a mean value of 172.3 mg/dL (SD=46.3). 
Triglyceride levels were documented in 57 charts (Table 6). These levels ranged from 73 
mg/dl to 660 mg/dL with a mean of 206.4 mg/dL (SD=136.3). The majority of the 
readings, 96.5% (n=53), were under 500 mg/dL and 49.1% (n= 28) were under 149 
mg/dL. Just 3.5% (n=2) were above 500 mg/dL. Table 7 displays the HDL levels, which 
were recorded in 55 charts and ranged in value from 3 mg/dL to 64 mg/dL, with a mean 
value of 33.9 mg/dL (SD=12.3).






Normal (0 to 149mg/dl) 28 13.9 50.9 50.9
Elevated (150 or more 
mg/dl) 27 13.4 49.1 100.0
Total 55 27.2 100.0
Missing System 147 72.8
Total 202 100.0
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HDL 11 to 15 1 .5 1.8 1.8
Levels 16 to 20 6 3.0 10.9 12.7
(mg/dL) 21 to25 7 3.4 12.7 25.5
26 to 30 10 4.9 18.2 43.6
31 to 35 5 2.5 9.1 52.7
36 to 40 9 4.4 16.4 69.1
41 to 45 6 3.0 10.9 80.0
46 to 50 6 3.0 10.9 90.9
50 or higher 5 2.5 9.1 100.0
Total 55 27.1 100.0
Missing System 148 72.9
Total 203 100.0
Altogether, 50 charts contained information on LDL levels. These ranged from 
38 mg/dL to 189 mg/dL with a mean value of 101.4 mg/dL (SD=41.5). There were a 
total of 17 with values over 100 mg/dL.
Overall, 40 of the charts reviewed did not contain a record of the medications 
listed on the Metabolic Syndrome Risk Factor Assessment Chart. Of the other 162 
charts, 39.2% (n=80) contained a record of a prescription for Aspirin, 37.1% (n=91) for a 
diuretic, 33.2% (n=67) for a statin, 31.7% (n=64) for a beta blocker, 29.2% (n=59) for an 
angiotensin converting enzyme (ACE) inhibitor, 19.3% (n=39) for a calcium channel 
blocker, 9.4% (n=19) for metformin, 5% (n=10) for a thiazolidinedione, and 4.5% (n=9) 
for an angiotensin receptor blocker (ARB). Besides these fibrates and niacin were both 
prescribed in 2% of the cases, and fish oil was used in just one percent of cases. The use 
of anorexic agents, orlistat, rosiglitazone, and pioglitazone were not seen. Medications 
listed in the “Other” category on the Metabolic Syndrome Risk Factor Assessment Chart 
included 10 other drugs or categories of drugs. Of these the most commonly prescribed
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ones were nitrates, documented in 24 charts, sulfonylureas in 16 charts, and antiplatelet 
drugs in 14 of the charts. Others included anticoagulants documented in 7 charts, 
antiarrhythmics in 2 charts and colestid, zetia, omega 3, and flax each in one chart.
Few referrals were made for a dietician or eye examination. A total of three 
referrals documented for a client to see a dietician, one for an eye exam, and 55 foot 
exams were completed or requested. Altogether, three nutrition/diet assessments were 
reported in the charts. There was not documentation found showing any of the clients 
received instruction on the importance of exercise. Diabetes education was noted to have 
been provided to six patients. Electrocardiograms were documended in 130 of the charts. 
Overall 56 of the charts reviewed noted that the client smoked. In 142 of the charts, the 
client was recorded as not smoking and the data was missing in four of the charts. Of the 
202 charts reviewed, information on alcohol use was documented in 198 charts, with 94 
consuming alcohol.
Of those with the MS, all but one received at least one intervention in terms of 
prevention or treatment. Of the 175 in the sample who received medication, a referral, 
nutrition/diet assessment, diabetes education, or an electrocardiogram, there were 16 
females and 29 males who had one of these interventions. There were 48 women and 48 
men who received two of these interventions/treatments, 13 women and 16 men who 
received three, and three women and two men who received four.
Research Questions One and Two: Comparison of the Metabolic Syndrome Risk Factors
between the Age Groups and Genders
With data for questions one and two covering much of the same information, they 
are discussed here in the same section. The five risk factors of elevated blood pressure,
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elevated blood glucose levels, high BMI level, high triglyceride level, and low HDL level 
are addressed in terms of how they compare between the genders and age groups.
Elevated Blood Pressure or Diagnosis o f Hypertension
From the total sample 58.4% (n=l 18) had hypertension. For those diagnosed 
with hypertension, 7.6% (n=9) were in the 20 to 40 age group, 43.2% (n=51) in the 41 to 
60 age group, 44.9% (n=53) in the 60 to 80 age group, and 4.2% (n=5) in the 81 to 100 
age group (Table 8). Of the 68 with a blood pressure reading over 130/85 mmHg, 13.2% 
were in the 20 to 40 age group, 57.4% in the 41 to 60 age group, 26.5% in the 60 to 80 
age group, and 2.9% in the age 81 to 100 age group (Table 9). A greater number of 
males (n=24) had a systolic reading over 130 mmHg, along with a diastolic reading over 
85 mmHg, than did females (n=17). There were 60 females and 58 males with a 
diagnosis of hypertension in their record.
When looking at the systolic blood pressure alone, 90% (n=45) of females with a 
reading over 130 mmHg had a reading between 130 mmHg and 179 mmHg, and 10% had 
a reading between 180 mmHg and 229 mmHg. Among females with a diastolic reading 
of over 85 mmHg, 60% (n=9) had a reading between 85 mmHg and 89 mmHg, 6.7% 
(n=l) between 90 mmHg and 94 mmHg, and 33.3% (n=5) between 95 mmHg and 99 
mmHg. There were 15 females and 12 males with a systolic blood pressure over or equal 
to 160 mgHg. For males with a systolic reading over 130 mmHg the majority, 95.2% 
(n=59) had a reading between 130 mmHg and 179 mmHg. The other 4.8% (n=3) were 
between 180 mmHg and 229 mmHg. Among those males with diastolic readings over 85 
mmHg, 50.0% (n=9) were between 85 mmHg and 89 mmHg, 33.3% (n=6) between 90 
mmHg and 94 mmHg, and 16.7 (n=3) between 95 mmHg and 99 mmHg.
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Table 8. Age Group of those Diagnosed with Hypertension





20-40 Count 24 9 33
Expected Count 12.8 20.2 33.0
%  within Age Group 27.7 % 27.3% 100.0%
% within H TN  Dx 32.0% 7.6% 17.1%
% within Total 12.4% 4.7% 17.1%
41-60 Count 32 51 83
Expected Count 32.3 50.7 83.0
% w ithin A ge Group 38.6% 61.4% 100.0%
% within H TN  Dx 42.7% 43.2% 43.0%
%  within Total 16.6% 26.4% 43.0%
61-80 Count 16 53 69
Expected Count 2 6 .8 4 2 .2 69 .0
%  within Age Group 2 3 .2 % 76 .8% 100 .0%
%  within H TN  Dx 2 1 .3 % 4 4 .9 % 35 .8%
%  within Total 8 .3% 27 .5% 35 .8%
81-100 Count 3 5 8
Expected Count 3.1 4 .9 8.0
%  within Age Group 37 .5% 62 .5% 100 .0%
% within H TN  Dx 4 .0% 4 .2% 4.1%
%  within Total 1 .6% 2.6% 4 .1%
Total Count 75 118 193
Expected Count 75 .0 118 .0 193 .0
% within Age Group 38 .9% 61 .1% 100 .0%
% within H TN  Dx 100 .0% 100 .0% 100 .0%
% within Total 3 8 .9 % 61 .1% 100 .0%
Note: A Pearson Chi-Square value of 23.07, df value of 3, p value of .00, and a Pearson R t
value of 4.34 was found when this data was analyzed.
Among both genders the majority with blood pressure readings over 130/85 
mmHg fell in the 41 to 60 age group (Table 10 and 11). The second largest number 
(n=12) among females were in the 61 to 80 age group, while among the males the 
numbers (n=6) were split equally between those in the 20 to 40 age group and 61 to 80 
age group.
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20-40 Count 26 9 35
Expected Count 23.1 11.9 35.0
% within Age Group 74.3 % 25.7% 100.0%
% within BP Group 19.7% 13.2% 17.5%
% within Total 13.0% 4.5% 17.5%
41-60 Count 46 39 85
Expected Count 56.1 28.9 85.0
% within Age Group 54.1% 45.9% 100.0%
% within BP Group 34.8% 57.4% 42.5%
% within Total 23.0% 19.5% 42.5%
61-80 Count 54 18 72
Expected Count 47.5 24.5 72.0
% within Age Group 75.0% 25.0% 100.0%
% within BP Group 40.9% 26.5% 36.0%
% within Total 27.0% 9.0% 36.0%
81-100 Count 6 2 8
Expected Count 5.3 2.7 8.0
% within Age Group 75.0% 25.0% 100.0%
% within BP Group 4.5% 2.9% 4.0%
% within Total 3.0% 1.0% 4.0%
Total Count 132 68 200
Expected Count 132.0 68.0 200.0
% within Age Group 66.0% 34.0% 100.0%
% within BP Group 100.0% 100.0% 100.0%
% within Total 66.0% 34.0% 100.0%
Note: A Pearson Chi-Square value of 9.31, df value of 3, p value of .025, and a Pearson 
R t value -.95 was found when this data was analyzed.
Altogether, 59.4% (n=60) of females and 57.4% (n=58) of males had 
hypertension. Among the females with a diagnosis of hypertension, the highest number, 
30, fell in the 61 to 80 age group (Table 12), while among the men with the diagnosis, the 
highest number, 29, fell in the 41 to 60 age group (Table 13).
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Table 10. Age Grouping o f Females with a Blood Pressure o f 130/85 or Greater
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
BP 130/85 No 19 21 26 2 68
or More Yes 3 15 12 2 32
Total 22 36 38 4 100
Note: A Pearson Chi-Square value of 5.55, df value of 3, g value of .14, and a 
Pearson R t value of 1.36 was found when this data was analyzed.
Table 11. Age Grouping of Males with a Blood Pressure of 130/85 or Greater
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
BP 130/85 No 7 25 28 4 64
or More Yes 6 24 6 36
Total 13 49 34 4 100
Note: A Pearson Chi-Square value of 11.39, df value of 3, g value of .01, and a Pearson R 
Lvalue of -3.05 was found when this data was analyzed.
Table 12. Age Groups of Females with a Diagnosis of Hypertension
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
Hypertension No 18 12 5 35
Dx Now Yes 4 22 30 4 60
Total 22 34 35 4 95
Note: A Pearson Chi-Square value of 29.15, df value of 3, g value of .00, and a Pearson R 
Lvalue of 6.08 was found when this data was analyzed.
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Table 13. Age Groups o f Males with a Diagnosis o f Hypertension
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
Hypertension No 6 20 11 3 40
Dx Now Yes 5 29 23 1 58
Total 11 49 34 4 98
Note: A Pearson Chi-Square value of 3.80, df value of 3, p value of .28, and a Pearson R t 
value of .47 was found when this data was analyzed.
Elevated Random Blood Glucose or Diagnosis o f Diabetes 
As there were very few fasting blood sugar readings, the focus here is on random 
glucose readings. Table 14 shows the number of random blood glucose readings over 
200 for males and females together. Of the 82 female patients with random glucose 
readings six were above 200 mg/dL (Table 15). The majority, 4, were between the values 
of 200 and 249 mg/dL. There was one in the 250 to 299 mg/dL group and another with a 
value between 300 and 349 mg/dL. For the males, there were ten charts, out of a total of 
91, with random blood sugar measurements over 200 mg/dL (Table 16). Of these, the 
majority, seven, again were in the 200 to 249 mg/dL range, with two between 250 and 
299 and one between 350 and 399 mg/dL. A greater number of males, 43 (Table 17), 
were diagnosed with diabetes than females, 35 (Table 18). Among the females diagnosed 
with diabetes, the highest number, 27, was in the 41 to 60 age group. This was also the 
case among males diagnosed with diabetes, with 36 in this age group. Among females 
with a blood glucose level over 200 mg/dL, most were between the age of 41 and 80 
(n=4) while among the men, the majority (n=5) was in the 20 to 40 age group.
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Valid 200 to 249 11 5.4 68.8 68.8
250 to 299 3 1.5 18.8 87.5
300 to 349 1 .5 6.3 93.8
350 to 399 1 .5 6.3 100.0
Total 16 7.9 100.0
Missing System 186 92.1
Total 202 100.0
Note: A Pearson Chi-Square value of 3.80, df value of 3, jd value of .28, and a 
Pearson R t_value of .47 was found when this data was analyzed.
Table 15. Age Groups and Random Glucose Category of Females
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
Glucose 200 t0 249 1 1 2 4
mg/dL 250 to 299 1 1
300 to 349 1 1
Total 1 2 2 1 6
Note: A Pearson Chi-Square value of 8.25, df value of 6, q. value of .22, and a Pearson R t 
value of .23 was found when this data was analyzed.
All but two of the 16 in the sample with a random blood sugar level over or equal 
to 200 mg/dL had a BMI over 30 kg/m2. Among those with diabetes, just two of the 16 
had a random blood sugar over or equal to 200 mg/dL. Eleven of the 16 had a blood 
pressure reading over or equal to 130/85 mmHg and 12 had a diagnosis of hypertension.
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Table 16. Age Groups and Random Glucose Category o f Males
Age Group
Total20 to 40 41 to 60 61 to 80
Glucose 200 to 249 3 3 1 7
Level 250 to 299 1 1 2
(m9' dL) 350 10 399 1 1
Total 5 3 2 10
Note: A Pearson Chi-Square value of 3.07, df value of 4, p value of .55, and a 
Pearson R t value o f-.60 was found when this data was analyzed.
Table 17. Age Group of Males with and without a Diagnosis of Diabetes
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
Diabetes No 7 36 14 1 58
Diagnosis Yes 6 14 20 3 43
Total 13 50 34 4 101
Note: A Pearson Chi-Square value of 9.80, df value of 3, p value of .02, and a 
Pearson R t value of 2.12 was found when this data was analyzed.
Table 18. Age Group of Females with and without a Diagnosis of Diabetes
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
Diabetes No 18 27 20 1 66
Diagnosis Yes 4 10 18 3 35
Total 22 37 38 4 101
Note: A Pearson Chi-Square value of 9.18, df value of 3, p value of .03, and a 
Pearson R t value of .00 was found when this data was analyzed.
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Body Mass Index
In Table 19 the majority, 43.8% (n=77), of those with a BMI over 30 kg/m2 were 
in the 41 to 60 age group. After this, the largest group was those in the 61 to 80 age 
group, 35.2% (n=62) of whom had a BMI over 30 kg/m2. The 20 to 40 age group had 
17.0% (n=30) of individuals with a BMI over 30 kg/m2, and the 81 to 100 age group had 
the remaining 4.0% (n=7). Among those with a BMI level between 20 kg/m2 and 29 
kg/m2 there were twice the number of men, 10, (Table 20) than women (Table 21). In the 
BMI category of 30 kg/m to 39 kg/m , there were 45 women and 62 men. The majority 
of those with a BMI over 39 kg/m2 had a level between 40 kg/m2 and 59 kg/m2, with 40 
females and 54 males having a BMI level between 40 kg/m2 and 49 kg/m2, and 36 
females and 21 males having a BMI level between 50 kg/m2 and 59 kg/m2. Above this 
level there were four females with a BMI of 60 kg/m2 to 69 kg/m2 and one with a BMI 
between 70 kg/m and 79 kg/m . Among the males, there were three with a BMI of 60 
kg/m2 to 69 kg/m2 and one with a BMI between 70 kg/m2 and 79 kg/m2. Those women 
with a BMI under 30 kg/m2 (n=5) fell into the age 61 to 80 age group (n=4) and age 20 to 
40 age group (n=l). Among men there was a wider range, with four men having a BMI 
under 30 kg/m2 in the 61 to 80 age group, three in the 41 to 60 age group, two in the 20 to 
40 age group, and one in the 81 to 100 age group. Women with a BMI over 30 kg/m2 
tended to be older, with the largest number of women in this category, 33, in the 61 to 80 
age group, 32 in the 41 to 60 age group, 19 in the 20 to 40 age group and 4 in the 81 to 
100 age group. Among the men with a BMI over 30 kg/m2, 45 were in the 41 to 60 age 
group, 29 in the 60 to 80 age group, 11 in the 20 to 40 age group, and three in the 81 to 
100 age group. Looking at the males in terms of their category of BMI, the highest
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number, 32 had a BMI between 30 kg/m2 and 34.9 kg/m2 while among the females the 
highest number, 43, had a BMI above 40 kg/m2.
Table 19. Body Mass Index Category and Age Group of Total Sample
Age Group Body Mass 
Index 20 to 
29.9 k g /m 2
Body Mass 
Index Over 
30 k g /m 2
Total
20-40 Count 3 30 33
Expected Count 2.6 30.4 33.0
% within Age Group 9.1 % 90.9% 100.0%
% within BMI Group 20.0% 17.0% 17.3%
% within Total 1.6% 15.7% 17.3%
41-60 Count 3 77 80
Expected Count 6.3 73.7 8.0
% within Age Group 3.8% 96.3% 100.0%
% within BMI Group 20.0% 43.8% 41.9%
% within Total 1.6% 40.3% 41.9%
61-80 Count 8 62 70
Expected Count 5.5 64.5 70.0
% within Age Group 11.4% 88.6% 100.0%
% within BMI Group 53.3% 35.2% 36.6%
% within Total 4.2% 32.5% 36.6%
81-100 Count 1 7 8
Expected Count .6 7.4 8.0
% within Age Group 12.5% 87.5% 100.0%
% within BMI Group 6.7% 4.0% 4.2%
% within Total .5% 3.7% 4.2%
Total Count 15 176 191
Expected Count 15.0 176.0 191.0
% within Age Group 7.9% 92.1% 100.0%
% within BMI Group 100.0% 100.0% 100.0%
% within Total 7.9% 92.1% 100.0%
Note: A Pearson Chi-Square value of 3.41, df value of 3, 2 value of .33, and a 
Pearson R t value o f-.96 was found when this data was analyzed.
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Table 20. Body Mass Index Category and Age Group o f Males
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
BMI Class 0 (20 to 29.9) 2 3 4 1 10
Category class 1 (30 to 34.9) 5 14 12 1 32
Class 2 (35 to 39.9) 4 17 7 1 29
Class 3 (40 or over) 2 14 9 1 26
Total 13 48 32 4 97
Note: A Pearson Chi-Square value of 4.66, df value of 9, p value of .86, and a Pearson R t value of .92 
was found when this data was analyzed.
Table 21. Body Mass Index Category and Age Group of Females
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
BMI Class 0 (20 to 29.9) 1 4 5
Category class 1 (30 to 34.9) 2 5 8 3 18
Class 2 (35 to 39.9) 5 9 13 27
Class 3 (40 or over) 12 18 12 1 43
Total 20 32 37 4 93
Note: A Pearson Chi-Square value of 16.79, df value of 9, p value of 0.05, and a Pearson R t value of .01 
was found when this data was analyzed.
Triglycerides
There were 11 females and 16 males with a triglyceride level over 150 mg/dL 
(Table 22). There were also 11 females with a reading under 150 mg/dL; among the 
males, there were 17 with a reading under that level. Among the 11 females with 
readings over 150 mg/dL there were 6 with readings between 150 mg/dL and 249 mg/dL,
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four with readings between 250 mg/dL and 349 mg/dL, and one with a reading between 
350 mg/dL and 449 mg/dL. No readings were above 449 mg/dL. Among males, the 
majority of those with readings above 150 mg/dL had levels between 150 mg/dL and 449 
mg/dL. There were 6 with readings between 150 mg/dL and 249 mg/dL, 4 each with 
readings between 250 mg/dL and 349 mg/dL and 350 mg/dL and 449 mg/dL, two with 
reading between 450 mg/dL and 549 mg/dL, and one each with a reading between 550 
mg/dL and 649 mg/dL and 650 mg/dL and 749 mg/dL.
Considering the various age groups, the age category with the highest numbers of 
cases with readings over 150 mg/dL was the age 61 to 80 category (n=l 1), followed by 
the 41 to 60 age category (n=T0), the age 20 to 40 category (n=4), and the age 81-100 
category (n=3) (Table 23). The majority of females (n=5) with triglyceride levels above 
150 mg/dL were between the age of 61 and 80 (Table 24) while the majority of males 
(n=8) with levels over 150 mg/dL were in the 41 to 60 age group (Table 25).
High Density Lipoprotein Cholesterol
Data was available on HDL levels for 21 females. As seen on Table 26 there 
were 12 females with HDL levels below 40 mg/dL of which the majority, four, had a 
level between 21 mg/dL and 25 mg/dL. There were three between the level of 26 mg/dL 
and 30 mg/dL, two between the level of 36 mg/dL and 40 mg/dL, and one each in the 
categories 31 mg/dL to 35 mg/dL, 16 mg/dL to 20 mg/dL and 11 mg/dL to 15 mg/dL. 
Among the 8 females with HDL levels above 40 mg/dL, there were three each with 
readings between 41 mg/dL to 45 mg/dL, and 51 mg/dL to 55 mg/dL, and two between 
the levels 46 mg/dL to 50 mg/dL.
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Note: A Pearson Chi-Square value of .12, df value of 1, p value of .91, and a Pearson R t 
value of -.11 was found when this data was analyzed.
Of the females with HDL levels 40 mg/dL or below, the majority, five, were in 
the 61 to 80 age group, followed by three in each of the 20 to 40 and 41 to 60 age groups, 
and two in the 81 to 100 age group. By dividing the HDL category into increments of 
five the highest percentage, 66.7%, was between 11 mg/dL and 40 mg/dL; the most 
represented increment according to age group fell between 26 mg/dL and 30 mg/dL, 
which was in the 20 to 40 age category.
44
Table 23. Age Group of Those with a Triglyceride Level under and Over 150 mg/dL







20-40 Count 4 4 8
Expected Count 4.1 3.9 8.0
% within Age Group 50.0 % 50.0% 100.0%
% within Trig Group 14.8% 14.8% 14.5%
% within Total 7.3% 7.3% 14.5%
41-60 Count 9 10 19
Expected Count 9.7 9.3 19.0
% within Age Group 47.4% 52.6% 100.0%
% within Trig Group 32.1% 37.0% 34.5%
% within Total 16.4% 18.2% 34.5%
61-80 Count 12 11 23
Expected Count 11.7 11.3 23.0
% within Age Group 52.2% 47.8% 100.0%
% within Trig Group 42.9% 40.7% 41.8%
% within Total 21.8% 20.0% 41.8%
81-100 Count 3 2 5
Expected Count 2.5 2.5 5.0
% within Age Group 60.0% 40.0% 100.0%
% within Trig Group 10.7% 7.4% 9.1%
% within Total 5.5% 3.6% 9.1%
Total Count 28 27 55
Expected Count 28.0 27.0 55.0
% within Age Group 50.9% 49.1% 100.0%
% within Trig Group 100.0% 100.0% 100.0%
% within Total 50.9% 49.1% 100.0%
Note: A Pearson Chi-Square value of .28, df value of 3, g value of .96, and a 
Pearson R t value of -.40 was found when this data was analyzed.
Table 24. Age Group and Triglyceride Level of Females
Age Group
Total20 to 40 41 to 60 61 to 80 81 to 100
Triglycerides 150 to 249 1 2 2 1 6
(mg/dL) 250 to 349 1 2 1 4
350 to 449 1 1
Total 1 3 5 2 11
Note: A Pearson Chi-Square value of 2.35, df value of 6, g value of .89, and a Pearson R t value of 
.82 was found when this data was analyzed.
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Table 25. Age Group and Triglyceride Level o f Males
Age Group
Total20 to 40 41 to 60 61 to 80
Triglycerides 150 to 249 5 1 6
(mg/dL) 250 to 349 1 3 4
350 to 449 2 1 1 4
450 to 549 1 1 2
550 to 649 1 1
650 to 749 1 1
Total 4 8 6 18
Note: A Pearson Chi-Square value of 14.94, df value of 10, p value of .13, and a 
Pearson R t value of -1.07 was found when this data was analyzed.
There were 28 males with an HDL level under 50 mg/dL out of the total of 34 
with data on HDL available. HDL was examined by dividing into increments of 5 from 
11 mg/dL to 50 mg/dL. The largest number of men (n=4), according to HDL category 
and age group, fell in the 26 to 30 mg/dL HDL level and were from the 61 to 80 age 
group. According to age group and percentages, the highest percentage, 100.0% (n=2), 
fell in 46 mg/dL to 50 mg/dL HDL and 80 to 100 age category. After this, the highest 
percentages were in the 20 to 40 age group, with 40.0% (n=2) in each of the 21 mg/dL to 
25 mg/dL group and in the 31 mg/dL to 35 mg/dL group of HDL levels.
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Table 26. High Density Lipoprotein Level According to Age Group among Females
H igh D e n s ity  L ip o p ro te in  C a te g o ry  
(m g /d L )
A g e  2 0 -4 0 A g e  4 1 -6 0 A g e  6 1 -8 0 A g e  8 1 -1 0 0 T o ta l
11-15 C ount 0 0 1 0 1
E xpected  C ount .1 .3 .4 .1 1.0
%  w ith in  H D L  C ategory .0 % .0% 100.0% .0 % 1 0 0 .0 %
%  w ith in  A ge G roup .0% .0% 11.1% .0% 4.8%
%  w ith in  T ota l .0% .0% 4.8% .0% 4.8%
16-20 C ount 1 0 0 0 1
E xpected  C ount .1 .3 .4 .1 1.0
%  w ith in  H D L  C ategory 100.0% .0 .0% .0% 100.0%
%  w ith in  A ge G roup 33.3% .0% .0% .0% 4.8%
%  w ith in  Total 4 .8% .0% .0% .0% 4.8%
21-25 C ount 0 1 2 1 4
E xpected  C ount .6 1.1 1.7 .6 4.0
%  w ith in  H D L  C ategory .0 % 25 .0% 50.0% 25.0  % 1 0 0 .0 %
%  w ith in  A ge  G roup .0% 16.7% 22.2% 33.3% 19.0%
%  w ith in  Total .0% 4.8% 9.5% 4.6% 19.0%
26-30 C oun t 2 1 l_o 0 3
E xpected  C ount .4 .9 1.3 .4 3.0
%  w ith in  H D L  C ategory 66 .7% 33.3 .0% .0% 100.0%
%  w ith in  A ge G roup 66 .7% 16.7% .0% .0% 14.3%
%  w ith in  T otal 9 .5% 4.8% .0% .0% 14.3%
3 1 -3 5 C ount 0 0 1 0 1
E xpected  C ount .1 .3 .4 .1 1.0
%  w ith in  H D L  C ategory .0 % .0% 100.0% .0 % 100.0 %
%  w ith in  A ge G roup .0% .0% 11.1% .0% 4.8%
%  w ith in  T ota l .0% .0% 4.8% .0% 4.8%
36-40 C ount 0 1 1 1 3
E xpected  C ount .4 .9 1.3 .4 3.0
%  w ith in  H D L  C ategory .0% 33.3 33.3% 33.3% 100.0%
%  w ith in  A ge  G roup .0% 16.7% 11.1% 33.3% 14.3%
%  w ith in  T otal .0% 4.8% 4.8% 4.8% 14.3%
41-45 C oun t 0 2 0 n 3
E xpected  C oun t .4 .9 1.3 .4 3.0
%  w ith in  H D L  C ategory .0 % 66.7% .0% 33.3 % 100.0 %
%  w ith in  A ge G roup .0% 33.3% .0% 33.3% 14.3%
%  w ith in  T ota l .0% 9.5% .0% 4.8% 14.3%
46-50 C ount 0 1 1 0 2
E xpected  C oun t .3 .6 .9 .3 2.0
%  w ith in  H D L  C ategory .0 % 50.0% 50.0% .0 % 100.0 %
%  w ith in  A ge G roup .0% 16.7% 11.1% .0% 9.5%
%  w ith in  T ota l .0% 4.8% 4.8% .0% 9.5%
>51 C ount 0 0 3 0 3
E xpected  C oun t .4 .9 1.3 .4 3.0
%  w ith in  H D L  C ategory .0% .0% 100.0% .0% 100.0%
%  w ith in  A ge G roup .0% .0% 33.3% .0% 14.3%
%  w ith in  T otal .0% .0% 14.3% .0% 14.3%
T otal C ount 3 6 9 3 21
E xpected  C ount 3.0 6.0 9.0 3.0 21.0
%  w ith in  H D L  C ategory 14.3% 28.60% 42.9% 14.3% 100.0%
%  w ith in  A ge G roup 100.0% 100.0% 100.0% 100.0% 100.0%
%  w ith in  T ota l 14.3% 28.6% 42.9% 14.3% 100.0%
Note: A Pearson Chi-Square value of 27.32, df value of 24, jd value of .29, and a Pearson R t value of 
.97 was found when this data was analyzed.
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Table 27. High Density Lipoprotein Levels According to Age Group among Males
High Density Lipoprotein 
Category (mg/dL)
Age 20-40 Age 41-60 Age 61-80 Age 81-100 Total
16-20 C ount 1 1 3 0 5
E xpected  C ount .7 2.1 1.9 .3 5.0
%  w ith in  H D L  G roup 20.0  % 20.0% 60.0% .0 % 1 0 0 .0 %
%  w ith in  A ge G roup 20 .0% 7.1% 23.1% .0% 14.7%
%  w ith in  T otal 2 .9% 2.9% 8.8% .0% 14.7%
21-25 C ount 2 1 0 0 3
E xpected  C ount .4 1.2 1.1 .2 3.0
%  w ith in  H D L  G roup 66 .7% 33.3 .0% .0% 100.0%
%  w ith in  A ge G roup 40 .0% 7.1% .0% .0% 8.8%
%  w ith in  T otal 5.9% 2.9% .0% .0% 8.8%
26-30 C ount 0 3 4 0 7
E xpected  C ount 1.0 2.9 2.7 .4 7.0
%  w ith in  H D L  G roup .0 % 42.9% 57.1% .0 % 1 0 0 .0 %
%  w ith in  A ge G roup .0% 21.4% 30.8% .0% 20.6%
%  w ith in  T ota l .0% 8.8% 11.8% .0% 20 .6%
31-35 Count 2 2 0 0 4
E xpected  C ount .6 1.6 1.5 .2 4 .0
%  w ith in  H D L  G roup 50.0% 50.0 .0% .0% 100.0%
%  w ith in  A ge G roup 40 .0% 14.3% .0% .0% 11.8%
%  w ith in  T otal 5.9% 5.9% .0% .0% 11.8%
3 6 -4 0 C ount 0 3 3 0 6
E xpected  Count .9 2.5 2.3 .4 6.0
%  w ith in  H D L  G roup .0 % 50.0% 50.0% .0 % 1 0 0 .0 %
%  w ith in  A ge G roup .0% 21.4% 23.1% .0% 17.6%
%  w ith in  Total .0% 8.8% 8.8% .0% 17.6%
41-45 C ount 0 1 2 0 3
E xpected  C ount .4 1.2 1.1 .2 3.0
%  w ith in  H D L  G roup .0% 33.3% 66.7% .0% 100.0%
%  w ith in  A ge G roup .0% 7.1% 15.4% .0% 8.8%
%  w ith in  T otal .0% 2.9% 5.9% .0% 8.8%
46-50 C ount 0 2 0 2 4
E xpected  C ount .6 1.6 1.5 .2 4.0
%  w ith in  H D L  G roup .0 % 50.0% .0% 50.0  % 100.0 %
%  w ith in  A ge G roup .0% 14.3% .0% 100.0% 11.8%
%  w ithin T otal .0% 5.9% .0% 5.9% 11.8%
>51 C ount 0 1 1 0 2
E xpected  C ount .3 .8 .8 .1 2 .0
%  w ith in  H D L  G roup .0 % 50.0% 50.0% .0 % 1 0 0 .0 %
%  w ith in  A ge G roup .0% 7.1% 7.7% .0% 5.9%
%  w ith in  T ota l .0% 2.9% 2.9% .0% 5.9%
T otal C ount 5 14 13 2 34
E xpected  C ount 5.0 14.0 13.0 2.0 34.0
%  w ith in  H D L  G roup 14.7% 41.2% 38.2% 5.9% 100.0%
%  w ith in  A ge G roup 100.0% 100.0% 100.0% 100.0% 100.0%
%  w ith in  Total 14.7% 41.2% 38.2% 5.9% 100.0%
Note: A Pearson Chi-Square value of 34.57, df value of 21, jd value of .03, and a Pearson R t value of 
1.61 was found when this data was analyzed.
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Question Three: Difference in Preventative Measures and Treatments between Genders
and Age Groups
Medications
As mentioned above, the most frequently prescribed medications listed in the 
Metabolic Syndrome Risk Factor Assessment Chart were aspirin (39.2%), diuretic 
(33.2%), statin (31.7%), beta blocker (29.2%), and ACE inhibitor (19.3%). Among 
women the largest percentage on aspirin (55.3%, n=21), a diuretic (56.3%, n=9) a statin 
(58.1%, n=18), beta blocker (53.3%, n=16), or an ACE inhibitor (50.0%, n=12) fell in the 
61 to 80 age group. Of the men on aspirin the majority, 42.9% (n=18), were younger 
fitting in the 41 to 60 age group. The largest percentage of men on a statin (47.2%, 
n=17), diuretic (45.0%, n=9) beta blocker (47.1%, n=16), or an ACE inhibitor (40.0%, 
n=14) were in the 61 to 80 age group.
Among those with a glucose level under 200 mg/dL the majority, 60% (n=33) 
were on just one of the medications listed in the Metabolic Syndrome Risk Factor 
Assessment Chart (Table 28). Another 14 (25.5%) were on two medications, five (9.1%) 
one three, two (3.6%) on four and one (1.8%) on five. Among those with a glucose level 
over 200 mg/dL there were a larger percentage, 37.5% (n=3), on two medications, 50% 
(n=4) on one medication and 12.5% (n=l) on four medications.
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Table 28. Number of Medications Used by Those with a Random Blood Sugar Level 
Above and Below 200 mg/dL


















Under Count 33 14 5 2 1 55
199 Expected Count 32.3 14.8 4.4 2.6 .9 55.0
% within Glucose Level 60.0 % 25.5% 9.1% 3.6% 1.8% 100.0%
% within Total No. of Meds 89.2% 82.4% 100.0% 66.7% 100.0% 87.3%
% within Total 52.4% 22.2% 7.9% 3.2% 1.6% 87.3%
200 Count 4 3 0 1 0 8
and Expected Count 4.7 2.2 .6 .4 .1 8.0
Over % within Glucose Level 50.0% 37.5% .0% 12.5% .0% 100.0%
% within Total No. of Meds 10.8% 17.6% .0% 33.3% .0% 12.7%
% within Total 6.3% 4.8% .0% 1.6% .0% 12.7%
Total Count 37 17 5 3 1 63
Expected Count 37.0 17.0 5.0 3.0 1.0 63.0
% within Glucose Level 58.7% 27.0% 7.9% 4.8 % 1.6% 100.0 %
% within Total No. of Meds 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 58.7% 27.0% 7.9% 4.8% 1.6% 100.0%
Note: A Pearson Chi-Square value of 2.52, df value of 4, p value of .64, and a Pearson R t value of .37 was found 
when this data was analyzed.
Referring to Table 29, among those with a diagnosis of diabetes there were 57.5% 
(n=23) on one medication compared to 61.5% (n=16) without the diagnosis of diabetes 
on one medication. There were 27.5% (n=l 1) of those with diabetes on two medications 
compared with 26.9% (n=7) of those without diabetes on two medications. Among those 
on three medications there were 3 with diabetes and two without. Those on four 
medications (n=3) all had diabetes, whereas the one person on five medications did not 
have diabetes.
Comparing those with blood pressure reading of 130/85 mmHg or over and the 
number of medications taken, it was found that the majority, 60.9% (n=14), took just one 
medication (Table 30). There were 21.7% (n=5) taking two medications, 8.7% (n=2) 
each taking four and five medications. Of those with a blood pressure under 130/85 
mmHg, there was a slightly lower percentage, 58.1% (n=25), taking one medication,
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30.2% (n-13) taking two, 7.0% (n=3) taking three and 2.3% (n=l) each taking four and 
five medications.
Table 29. Number of Medications Used by Those with a Diagnosis of Diabetes






1 Count 16 23 39
Expected Count 15.4 23.6 39.0
% within Total No. of Meds 41.0 % 59.0% 100.0%
% within Diabetes Dx. 61.5% 57.5% 59.1%
% within Total 24.2% 34.8% 59.1%
2 Count 7 11 18
Expected Count 7.1 10.9 18.0
% within Total No. of Meds 38.9% 61.1% 100.0%
% within Diabetes Dx. 26.9% 27.5% 27.3%
% within Total 10.6% 16.7% 27.3%
3 Count 2 3 5
Expected Count 2.0 3.0 5.0
% within Total No. of Meds 40.0% 60.0% 100.0%
% within Diabetes Dx. 7.7% 7.5% 7.6%
% within Total 3.0% 4.5% 7.6%
4 Count 0 3 3
Expected Count 1.2 1.8 3.0
% within Total No. of Meds .0% 100.0% 100.0%
% within Diabetes Dx. .0% 7.5% 4.5%
% within Total .0% 7.5% 4.5%
5 Count 1 0 1
Expected Count .4 .6 1.0
% within Total No. of Meds 100.0% .0% 100.0%
% within Diabetes Dx. 3.8% .0% 1.5%
% within Total 1.5% .0% 1.5%
Total Count 26 40 66
Expected Count 26.0 40.0 66.0
% within Total No. of Meds 39.4% 60.6% 100.0%
% within Diabetes Dx. 100.0% 100.0% 100.0%
% within Total 39.4% 60.6% 100.0%
Note: A Pearson Chi-Square value of 3.54, df value of 4, jd value of .47, and a Pearson R t 
value of .31 was found when this data was analyzed.
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Under Count 25 13 3 1 1 43
130/85 Expected Count 25.4 11.7 3.3 2.0 .7 43.0
mmHg % within BP Group 58.1 % 30.2% 7.0% 2.3% 2.3 % 100.0%
% within Med Group 64.1% 72.2% 60.0% 33.3% 100.0% 65.2%
% within Total 37.9% 19.7% 4.5% 1.5% 1.5% 65.2%
130/85 Count 14 5 2 2 0 23
mmHg Expected Count 13.6 6.3 1.7 1.0 .3 23.0
and % within BP Group 60.9% 21.7% 8.7% 8.7% .0% 100.0%
Over % within Med Group 35.9% 27.8% 40.0% 66.7% .0% 34.8%
% within Total 21.2% 7.6% 3.0% 3.0% .0% 34.8%
Total Count 39 18 5 3 1 66
Expected Count 39.0 18.0 5.0 3.0 1.0 66.0
% within BP Group 59.1% 27.3% 7.6% 4.5 % 1.5 % 100.0 %
% within Med Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 59.1% 27.3% 7.6% 4.5% 1.5% 100.0%
Note: A Pearson Chi-Square value of 2.35, df value of 4, p value of .67, and a Pearson R t value of .20 was 
found when this data was analyzed.
Those with a diagnosis of hypertension took more of the medications listed in the 
Metabolic Syndrome Risk Factor Assessment Chart than those who did not have the 
diagnosis. As seen in Table 31, there were 58.0% (n=29) with the diagnosis of 
hypertension compared to 61.5% (n=8) without who were on one medication, 24.0% 
(n=12) with the diagnosis and 29.4% (n=5) without the diagnosis on two medications, 
10.0% (n=5) with the diagnosis on three medications, 6.0% (n=3) with the diagnosis on 
four medications, and 2.0% (n=l) with the diagnosis on five medications. No one 
without the diagnosis of hypertension was on three or more medications.
52
Table 31. Number o f Medications Used by those with a Diagnosis of Hypertension







1 Count 8 29 37
Expected Count 7.6 29.4 37.0
% within Total Meds 21.6% 78.4% 100.0%
% within HTN Dx 61.5% 58.0% 58.7%
% within Total 12.7% 46.0% 58.7%
2 Count 5 12 17
Expected Count 3.5 13.5 17.0
% within Total Meds 29.4% 70.6% 100.0%
% within HTN Dx 38.5% 24.0% 27.0%
% within Total 7.9% 19.0% 27.0%
3 Count 0 5 5
Expected Count 1.0 4.0 5.0
% within Total Meds .0% 100.0% 100.0%
% within HTN Dx .0% 10.0% 7.9%
% within Total .0% 7.9% 7.9%
4 Count 0 3 3
Expected Count .6 2.4 3.0
% within Total Meds .0% 100.0% 100.0%
% within HTN Dx .0% 6.0% 4.8%
% within Total .0% 4.8% 4.8%
5 Count 0 1 1
Expected Count .2 .8 1.0
% within Total Meds .0% 100.0% 100.0%
% within HTN Dx .0% 2.0% 1.6%
% within Total .0% 1.6% 1.6%
Total Count 13 50 63
Expected Count 13.0 50.0 63.0
% within Total Meds 20.6% 79.4% 100.0%
% within HTN Dx 100.0% 100.0% 100.0%
% within Total 20.6% 79.4% 100.0%
Note: A Pearson Chi-Square value of 3.16, df value of 4, p value of .53, and 
a Pearson R t value of 1.08 was found when this data was analyzed.
Among those with a BMI of over 30 kg/m2, there were 60.3% (n=35) on one 
medication, 24.1% (n=14) on two medications, 8.6% (n=5) on three, 5.2% (n=3) on four, 
and 1.7% (n=l) on five. Looking at those with a BMI under 30 kg/m 2 there were none 
on three or more medications. There were, however, a higher percent, 42.9% (n=3), on 
two medications and just 57.1% (n=4) on one medication.
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There were seven subjects who had a triglyceride level over 150 mg/dL and were 
on one medication (Table 32). Among the other seven with triglyceride levels over 150 
mg/dL, there were four on two medications, one on three medications, and two on four 
medications. Among those with a triglyceride level under 150 mg/dL the distribution of 
medications was approximately the same, with six on one medication, four on two, three 
on three, one on four, and one on five.


















0-149 Count 6 4 3 1 1 15
mg/dL Expected Count 6.7 4.1 2.1 1.6 .5 15.0
% within Trig Group 40.0 % 26.7% 20.0% 33.3% 6.7 % 100.0%
% within Med Group 46.2% 50.0% 75.0% 33.3% 100.0% 51.7%
% within Total 20.7% 13.8% 10.3% 3.4% 3.4% 51.7%
200 Count 7 4 1 2 0 14
mg/dL Expected Count 6.3 3.9 1.9 1.4 .5 14.0
and % within Trig Group 50.0% 28.6% 7.1% 14.3% .0% 100.0%
Over % within Med Group 53.8% 50.0% 25.0% 66.7% .0% 48.3%
% within Total 24.1% 13.8% 3.4% 6.9% .0% 48.3%
Total Count 13 8 4 3 1 29
Expected Count 13.0 8.0 4.0 3.0 1.0 69.0
% within Trig Group 44.8% 27.6% 13.8% 10.3% 3.4 % 100.0%
% within Med Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 44.8% 27.6% 13.8% 10.3% 3.4% 100.0%
Note: A Pearson Chi-Square value of 2.38, df value of 4, jd value of .67, and a Pearson R t value of 
-.63 was found when this data was analyzed.
Among males with an HDL level under 50 mg/dL, there were 20.0% (n=3) each 
on two and five medications, 13.3% (n=2) each on one, three, four, and six medications, 
and 6.7% (n=l) on seven medications (Table 33). Among those with HDL levels above 
50 mg/dL there were none on more than four medications. There were 50.0% (n=l) on 
three medications, and 50.0% (n=l) on four medications.
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Table 33. Number of Medications Used by Males with a High Density Lipoprotein Level 
Above and Below 50 mg/dL




Lipoprotein Level 50 
mg/dL and Above
Total
1 Count 2 0 2
Expected Count 1.8 .2 2.0
% within Total Meds 100.0% .0% 100.0%
% within HDL Group 13.3% .0% 11.8%
% within Total 11.8% .0% 11.8%
2 Count 3 0 3
Expected Count 2.6 .4 3.0
% within Total Meds 100.0% .0% 100.0%
% within HDL Group 20.0% .0% 17.6%
% within Total 17.6% .0% 17.6%
3 Count 2 1 3
Expected Count 2.6 .4 3.0
% within Total Meds 66.7% 33.3% 100.0%
% within HDL Group 13.3% 50.0% 17.6%
% within Total 11.8% 5.9% 17.6%
4 Count 2 1 3
Expected Count 2.6 .4 3.0
% within Total Meds 66.7% 33.3% 100.0%
% within HDL Group 33.3% 50.0% 17.6%
% within Total 11.8% 5.9% 17.6%
5 Count 3 0 3
Expected Count 2.6 .4 3.0
% within Total Meds 100.0% .0% 100.0%
% within HDL Group 20.0% .0% 17.6%
% within Total 17.6% .0% 17.6%
6 Count 2 0 2
Expected Count 1.8 .2 2.0
% within Total Meds 100.0% .0% 100.0%
% within HDL Group 13.3% .0% 11.8%
% within Total 11.8% .0% 11.8%
7 Count 1 0 1
Expected Count .9 .1 1.0
% within Total Meds 100.0% .0% 100.0%
% within HDL Group 6.7% .0% 5.9%
% within Total 5.9% .0% 5.9%
Total Count 15 2 17
Expected Count 15.0 2.0 17.0
% within Total Meds 88.2% 11.8% 100.0%
% within HDL Group 100.0% 100.0% 100.0%
% within Total 88.2% 11.8% 100.0%
Note: A Pearson Chi-Square value of 4.16, df value of 6, g value of .66, and a Pearson R t value o f-.17 was 
found when this data was analyzed.
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The females with an HDL level over 40 mg/dL were taking between two and five
medications (Table 34). There were none on four medications, one each on three and
five medications, four on two medications, and six on one medication. Of the 17 females
with HDL levels under 40 mg/dL there were none on five medications, three each on
three and four medications, four on two medications, and seven on one medication.
Table 34. Number of Medications Used by Females with an High Density Lipoprotein 
Level Above and Below 40 mg/dL


















Under 40 Count 7 4 3 1 1 15
mg/dL Expected Count 7.6 4.7 2.3 1.6 .5 15.0
% within HDL Group 41.2 % 23.5% 1% 33.3% 6.7 % 100.0%
% within Med Group 53.8% 50.0% 75.0% 33.3% 100.0% 51.7%
% within Total 24.1% 13.8% 10.3% 3.4% 3.4% 51.7%
40 Count 7 4 1 2 0 14
mg/dL Expected Count 6.3 3.9 1.9 1.4 .5 14.0
and % within HDL Group 50.0% 28.6% 7.1% 14.3% .0% 100.0%
Over % within Med Group 53.8% 50.0% 25.0% 66.7% .0% 48.3%
% within Total 24.1% 13.8% 3.4% 6.9% .0% 48.3%
Total Count 13 8 4 3 1 29
Expected Count 13.0 8.0 4.0 3.0 1.0 69.0
% within HDL Group 44.8% 27.6% 13.8% 10.3% 3.4 % 100.0 %
% within Med Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 44.8% 27.6% 13.8% 10.3% 3.4% 100.0%
Note: A Pearson Chi-Square value of 4.34, df value of 4, p value of .36, and a Pearson R t value of 
-.64 was found when this data was analyzed.
Among those with a BMI over 30 kg/m2 the largest percent were on 4 (25.0%) or
5 (16.7%) medications (Table 35). Of those with a BMI below 30 kg/m2 there were none
on more than five medications while those with a BMI over 30 kg/m2 were taking up to 8
medications.
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Table 35. Number of Medications Used by Those with a Body Mass 
Index Above and Below 30 kg/m2
Number of Medications BMI 20-29.9 BMI 30 or More Total
1 Count 1 5 6
Expected Count .5 5.5 6.0
% within HDL Group 16.7% 83.3% 100.0%
% within Med Group 16.7% 8.3% 9.1%
% within Total 1.5% 7.6% 9.1%
2 Count 1 8 9
Expected Count .8 8.2 9.0
% within HDL Group 11.1% 88.9% 100.0%
% within Med Group 16.7% 13.3% 13.6%
% within Total 1.5% 12.1% 13.6%
3 Count 1 7 8
Expected Count .8 7.3 8.0
% within HDL Group 11.1% 87.5% 100.0%
% within Med Group 16.7% 11.7% 12.1%
% within Total 1.5% 10.6% 12.1%
4 Count 1 15 16
Expected Count 1.5 14.5 16.0
% within HDL Group 6.3% 93.8% 100.0%
% within Med Group 16.7% 25.0% 24.2%
% within Total 1.5% 22.7% 24.2%
5 Count 2 10 12
Expected Count 1.1 10.9 12.0
% within HDL Group 16.7% 83.3% 100.0%
% within Med Group 33.3% 16.7% 18.2%
% within Total 3.0% 15.2% 18.2%
6 Count 0 9 9
Expected Count .8 8.2 9.0
% within HDL Group .0% 100.0% 100.0%
% within Med Group .0% 15.0% 13.6%
% within Total .0% 13.6% 13.6%
7 Count 0 5 5
Expected Count .5 4.5 5.0
% within HDL Group .0% 100.0% 100.0%
% within Med Group .0% 8.3% 7.6%
% within Total .0% 7.6% 7.6%
8 Count 0 1 1
Expected Count .1 .9 1.0
% within HDL Group .0% 100.0% 100.0%
% within Med Group .0% 1.7% 1.5%
% within Total .0% 1.5% 1.5%
Total Count 6 60 66
Expected Count 6.0 60.0 66.0
% within HDL Group 9.1% 90.9% 100.0%
% within Med Group 100.0% 100.0% 100.0%
% within Total 9.1% 90.9% 100.0%
Note: A Pearson Chi-Square value of 3.06, df value of 7, g value of .88, and 
a Pearson R t value of 1.07 was found when this data was analyzed.
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Looking at the medications listed under “Other” on the Metabolic Syndrome Risk 
Factor Assessment Chart when comparing males and females, the highest number of 
females (n=24) and males (n=25) were on three medications. After this, the highest 
numbers among females were on one medication (n=19); 12 each were on two and four 
medications, and eight were on five medications. There were 27 females and 22 males 
not on any of the medications listed in the chart. Among the males, there were 17 on one 
medication, 14 on two medications, 13 on four medications, eight on five medications, 
two on six medications, and one on seven medications.
Dietician Referral & Nutrition/Diet Assessment 
There were three patients, two males (age 21 and 42) and one female (age 41), 
referred to a dietician. All of these three had BMI levels over 30 kg/m2 with two between 
30 kg/m2 and 40 kg/m2 and one between 40 kg/m2 and 50 kg/m2. One had a systolic 
blood pressure reading above 135 mmHg and one had a diastolic reading above 85 
mmHg. Another had a reading under 130/85 mmHg. Two did not have a diagnosis of 
hypertension and for the remaining subjects this data was missing. Two had a diagnosis 
of diabetes but only one had blood glucose reading over 200 mg/dL. Triglyceride and 
HDL levels were only available for one of the patients. He had a triglyceride level of 127 
mg/dL and an HDL level of 28 mg/dL. Only one of the three was on any of the 
medications listed on the Metabolic Syndrome Risk Factor Assessment Chart.
Three patients, two females and one male, were referred for a diet or nutrition 
assessment. Of these three, two were age 63 and one was 49 years old. The data on BMI 
was missing for one, for another is was 40.2 kg/m2, and for the third it was 30.7 kg/m2.
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For one of the three, the information on the diagnosis of hypertension was missing, and 
of the two who had a diagnosis one had hypertension and the other did not. The patient 
with hypertension was the only one with an elevated blood pressure at 140/74 mmHg.
The only one with a blood sugar reading over 200 mg/dL was also the only one 
diagnosed with diabetes. None had HDL or triglyceride readings available and two were 
on medications; one on one medication and the other on two.
Eye Examination, Exercise Counseling, & Foot Examination
There were no patients referred for an eye exam or for exercise counseling. There 
was also no documentation found encouraging patients to exercise. A total of 55 foot 
exam referrals or examinations were completed (Table 35). Thirty males and 25 females 
received foot exams or referrals for an examination. The largest number of exams were 
done on those between the ages of 41 and 60, while the highest percentage (29.2%) of 
exams according to age group were done on those in the 61 to 80 age group. Among 
women, the highest number (n=12) of foot exams was completed on those in the 41 to 60 
age group; the highest percentage (50.0%) of foot exams according to age group was 
done on the 61 to 80 age group. Among males, the highest number and percentage 
(34.0%, n=17) of foot exams completed were in the 41 to 60 age group.
Of those with a diagnosis of hypertension, 35 were referred for a foot exam or had 
one done during their visit. Among those with a blood pressure over 130/85 mmHg, 
30.9% (n=21) had a foot exam or referral for one, whereas among those with a blood 
pressure 130/85 mmHg or less, 25.8% had a foot exam or referral. Of the females with 
an HDL level under 40 mg/dL, 71.4% (n=15) had a foot exam done or a referral made. 
Among the 50 males with an HDL level under 50 mg/dL, 95.2% (n=20) had a foot exam
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or referral completed. Of those with a triglyceride level over 150 mg/dL, 40.7% (n=l 1) 
had a foot exam or referral. There were 50 with a BMI over 30 kg/m2 and three with a 
BMI under 30 kg/m2 who had a foot exam or referral for a foot examination.
Approximately the same percentage (31.3%) of those with a glucose reading over 
200 mg/dL as those (30.6%) with a reading under this level had a foot exam or referral 
made (Table 36). Of those with a diagnosis of diabetes, 34.6% (n=27) had a foot exam or 
referral for an exam (Table 37).
Table 36. Age Group of Those with Foot Exam Completed
Foot Exam Age 20- Age 41- Age 61- Age 81- Total
40 60 80 100
No Count 29 62 51 5 147
Expected Count 25.5 63.3 52.4 5.8 147.0
% within Foot Exam 19.7% 42.2% 34.7% 3.4% 100.0%
% within Age Group 82.9% 71.3% 70.8% 62.5% 72.8%
% within Total 14.4% 31.7% 25.2% 2.5% 72.8%
Yes Count 6 25 121 3 65
Expected Count 9.5 23.7 19.6 2.2 55.0
% within Foot Exam 10.9% 45.5% 38.2% 5.5% 100.0%
% within Age Group 17.1% 28.7% 29.2% 37.5% 27.2%
% within Total 3.0% 12.4% 10.4% 1.5% 27.2%
Total Count 35 87 72 8 202
Expected Count 35.0 87.0 72.0 8.0 202.0
% within Foot Exam 17.3% 43.1% 35.6% 4.0 % 100.0%
% within Age Group 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 17.3% 43.1% 35.6% 4.0% 100.0%
Note: A Pearson Chi-Square value of 2.46, df value of 3, jd value of .48, and a Pearson R t 
value of 1.32 was found when this data was analyzed.
60
Table 37. Foot Exams Completed on Those with a Random Blood Glucose Greater than 
or Less Than 200 mg/dL
Foot Exam
No Yes Total
Glucose 199 or less Count 109 48 157
(mg/dL) Expected Count 108.9 48.1 157.0
% within Q1 Glucose 200 69.4% 30.6% 100.0%
% within Foot Exam 90.8% 90.6% 90.8%
% of Total 63.0% 27.7% 90.8%
200 or more Count 11 5 16
Expected Count 11.1 4.9 16.0
% within Q1 Glucose 200 68.8% 31.3% 100.0%
% within Foot Exam 9.2% 9.4% 9.2%
% of Total 6.4% 2.9% 9.2%
Total Count 120 53 173
Expected Count 120.0 53.0 173.0
% within Q1 Glucose 200 69.4% 30.6% 100.0%
% within Foot Exam 100.0% 100.0% 100.0%
% of Total 69.4% 30.6% 100.0%
Note: A Pearson Chi-Square value of .00, df value of 1,2 value of .96, and a Pearson R t value of 
.06 was found when this data was analyzed.
Diabetes Education
Six patients, three males and three females, received a referral for diabetes 
education (Table 38). Of the females, one was in her forties, and the other two were in 
their sixties. Of the males, one was in his twenties, another in his forties, and the third in 
his fifties. Just one (0.8%) of those with a diagnosis of hypertension received a diabetes 
education referral. Three of the 50 males with an HDL under 50 mg/dL received a 
referral for diabetes education. Of the three females, two had an HDL level under 40 
mg/dL with the other having a level of 54 mg/dL. Twenty percent (n=l) of those with a 
glucose level of over 200 mg/dL received a referral for diabetes education. Of the 202 
with diabetes only five (2.5%) had a referral made for diabetes education.
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Table 38. Foot Exams Completed Among those with a Diagnosis of Diabetes
Diabetes Dx
No Yes Total
Foot Exam No Count 96 51 147
Expected Count 90.2 56.8 147.0
% within Foot Exam 65.3% 34.7% 100.0%
% within Diabetes Dx 77.4% 65.4% 72.8%
% of Total 47.5% 25.2% 72.8%
Yes Count 28 27 55
Expected Count 33.8 21.2 55.0
% within Foot Exam 50.9% 49.1% 100.0%
% within Diabetes Dx 22.6% 34.6% 27.2%
% of Total 13.9% 13.4% 27.2%
Total Count 124 78 202
Expected Count 124.0 78.0 202.0
% within Foot Exam 61.4% 38.6% 100.0%
% within Diabetes Dx 100.0% 100.0% 100.0%
% of Total 61.4% 38.6% 100.0%
Note: A Pearson Chi-Square value of 3.5, df value of 1, g value of .06, and a Pearson 
R t value of 1.88 was found when this data was analyzed.
Electrocardiogram
A total of 130patients, 63 females (Table 39) and 67 males (Table 40), had a 
record of an electrocardiogram (ECG) in their chart. The greatest percentage of those 
having had an ECG were between the ages of 41 and 60, with 43.8% (n=57) of those with 
an ECG being in the 61 to 80 age group, 43.1% (n=56) in the 41 to 60 age group, 8.5% 
(n=l 1) in the age 20 to 40 age group, and 4.6% (n=6) in the age 81 to 100 age bracket. 
Among both males and females the highest percentages (76.5% and 81.6% respectively) 
within an age group having ECGs fell in the 61 to 80 age group while the highest total 
number having an ECG was highest for men (n=32) in the 41 to 60 age group and highest, 
for women (n=31) in the 61 to 80 age group. A total of 56 (71.8%) of the 78 patients 
with diabetes had an ECG in their chart, whereas 86 (64.2%) of those with hypertension
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had an ECG on record. As seen in Table 41 of the 68 patients with a blood pressure over 
130/85 mmHg, 47 had an ECG done.
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Note: A Pearson Chi-Square value of 5.22, df value of 1, £> value of .02, and a Pearson R t value of 
2.3 was found when this data was analyzed.
A great majority, 65.3%, of those with a BMI over 30 kg/m2 had an ECG in their 
record. Among those with a triglyceride level over 150 mg/dL, 96.3% (n=26) had an 
ECG completed. Of those who had an ECG done, 8.5% (n=10) had a random blood 
glucose level over 200 mg/dL. Thirty six (94.7%) females with an HDL level under 40 
mg/dL received an ECG (Table 42). Table 43 shows that of the 50 males with an HDL 
level under 50 mg/dL, 47 (94.0%) received an ECG.
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Table 40. Age of Females Having an Electrocardiogram (EKG) on Record









No Count 18 13 7 0 38
Expected Count 8.3 13.9 14.3 1.5 38.0
% within EKG Exam 47.4 % 34.2% 18.4% .0% 100.0%
% within Age Group 81.8% 35.1% 18.4% .0% 37.6%
% within Total 17.8% 12.9% 6.9% .0% 37.6%
Yes Count 4 24 31 4 63
Expected Count 13.7 23.1 23.7 2.5 63.0
% within EKG Exam 6.3% 38.1% 49.2% 6.3% 100.0%
% within Age Group 18.2% 64.9% 81.6% 100.0% 62.4%
% within Total 4.0% 23.8% 30.7% 4.0% 62.4%
Total Count 22 37 38 4 101
Expected Count 22.0 37.0 38.0 4.0 101.0
% within EKG Exam 21.8% 36.6% 37.6% 4.0 % 100.0%
% within Age Group 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 21.8% 36.6% 37.6% 4.0% 100.0%
Note: A Pearson Chi-Square value of 26.79, df value of 3, jd value of .00, and a Pearson R t 
value of 5.60 was found when this data was analyzed.
Table 41. Age of Those Males Having an Electrocardiogram on Record









No Count 6 18 8 2 34
Expected Count 4.4 16.8 11.4 1.3 34.0
% within EKG Exam 17.6% 52.9% 23.5% 5.9% 100.0%
% within Age Group 46.2% 36.0% 23.5% 50.0% 33.7%
% within Total 5.9% 17.8% 7.9% 2.0% 33.7%
Yes Count 7 32 26 2 67
Expected Count 8.6 33.2 22.6 2.7 67.0
% within EKG Exam 10.4% 47.8% 38.8% 3.0% 100.0%
% within Age Group 53.8% 64.0% 76.5% 50.0% 66.3%
% within Total 6.9% 31.7% 25.7% 2.0% 66.3%
Total Count 13 50 34 4 101
Expected Count 13.0 50.0 34.0 4.0 101.0
% within EKG Exam 12.9% 49.5% 33.7% 4.0 % 100.0%
% within Age Group 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 12.9% 49.5% 33.7% 4.0% 100.0%
Note: A Pearson Chi-Square value of 3,07, df value of 3, g value of .38, and a Pearson R t 
value of 1.07 was found when this data was analyzed.
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Table 42. Number of Patients with a Blood Pressure of 130/85 mmHg or Greater with an 
Electrocardiogram on Record









No Count 49 83 132
Expected Count 46.2 85.8 132.0
% within BP Group 37.1 % 62.9% 100.0%
% within EKG Group 70.0% 63.8% 66.0%
% within Total 24.5% 41.5% 66.0%
Yes Count 21 47 68
Expected Count 23.8 44.2 68.0
% within BP Group 30.9% 69.1% 100.0%
% within EKG Group 30.0% 36.2% 34.0%
% within Total 10.5% 23.5% 34.0%
Total Count 70 130 200
Expected Count 70.0 130.0 200.0
% within BP Group 35.0% 65.0% 100.0%
% within EKG Group 100.0% 100.0% 100.0%
% within Total 35.0% 65.0% 100.0%
Note: A Pearson Chi-Square value of,77, df value of 1, jd value of .38, and a Pearson R t 
value of .87 was found when this data was analyzed.
Alcohol Use
A total of 94 people, or 46.5% of the sample, used alcohol. Out of these 94, 34 
were women and 60 were male. Of the women 33.7% used alcohol whereas 59.4% of 
males were recorded as using alcohol. The largest number using alcohol, 44, were in the 
41 to 60 age group while the largest percentage according to age group,
66.7%, were in the 20 to 40 age group (Table 44).
Of the females with an HDL under 40 mg/dL, 43.2% (n=16) used alcohol, 
whereas 72.2% (n=13) of females with an HDL level over 40 mg/dL used alcohol. Of 
those females who drank alcohol, 55.2% also had an HDL level under 40 mg/dL. There 
were 23 males who drank alcohol and also had an HDL level under 50 mg/dL. These 23 
made up 79.3% of all males who drank. Among those who did not drink 100.0% (n=26) 
had an HDL level under 50 mg/dL. Of the 16 with a glucose level over 200 mg/dL, 
56.3% (n=9) used alcohol, whereas 46.1% (n=71) of those with a glucose level under 200
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mg/dL used alcohol. Half of those who drank (n=13) had a triglyceride level over 150
mg/dL while the other half a level under 150 mg/dL.
Table 43. Number of Females with an High Density Lipoprotein Level 
Above and Below 40 mg/dL
Electrocardiogram
No Yes Total
HDL Normal (Less Count 36 38
(mg/dL) than 40mg/dl) Expected Count 2.0 36.0 38.0
% within Q1 - HDL 
Female 5.3% 94.7% 100.0%
% within
Electrocardiogram 66.7% 67.9% 67.9 %
% of Total 3.6% 64.3% 67.9%
Elevated (40 or Count 1 17 18
more mg/dl) Expected Count 1.0 17.0 18.0
% within Q1 - HDL 
Female 5.6% 94.4% 100.0%
% within
Electrocardiogram 33.3% 32.1% 32.1%
% of Total 1.8% 30.4% 32.1%
Total Count 3 53 56
Expected Count 3.0 53.0 56.0
% within Q1 - HDL 
Female 5.4% 94.6% 100.0%,
% within
Electrocardiogram 100.0% 100.0% 100.0%,
% of Total 5.4% 94.6% 100.0%,
Note: A Pearson Chi-Square value of,00, df value of 1, g value of .96, and a Pearson R t 
value o f -1.17 was found when this data was analyzed.
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Table 44. Number of Males with an High Density Lipoprotein Level Above and Below 
50 mg/dL Having a Record of an Electrocardiogram
Electrocardiogram
No Yes Total
HDL Normal (Less Count 3 47 50
(mg/dL) than 50mg/dl) Expected Count 2.7 47.3 50.0
% within Q1 - HDL Male 6.0% 94.0% 100.0%
% within
Electrocardiogram 100.0% 88.7% 89.3%
% of Total 5.4% 83.9% 89.3%
Elevated (50 or Count 0 6 6
more mg/dl) Expected Count .3 5.7 6.0
% within Q1 - HDL Male .0% 100.0% 100.0%,
% within
Electrocardiogram .0% 11.3% 10.7%
% of Total .0% 10.7% 10.7%
Total Count 3 53 56
Expected Count 3.0 53.0 56.0
% within Q1 - HDL Male 5.4% 94.6% 100.0%,
% within
Electrocardiogram 100.0% 100.0% 100.0%,
% of Total 5.4% 94.6% 100.0%
Note: A Pearson Chi-Square value of,38, df value of 1, £ value of .54, and a Pearson R t 
value of .61 was found when this data was analyzed.
Table 45. Alcohol Use According to Age Group









No Count 11 42 47 4 104
Expected Count 17.3 45.2 37.3 4.2 104.0
%> within AU Group 10.6 %0 40.4%, 45.2%, 3.8% 100.0%,
%> within Age Group 33.3%o 48.8% 66.2%, 50.0%, 52.5%
%  within Total 5.6%. 21.2%, 23.7%, 2.0% 52.5%,
Yes Count 22 44 24 4 94
Expected Count 15.7 40.8 33.7 3.8 94.0
%  within AU Group 23.4%> 46.8%, 25.5%, 4.3% 100.0%,
%  within Age Group 66.7% 51.2%, 33.8% 50.0%, 47.5%,
%  within Total 11.1% 22.2%, 12.1% 2.0% 47.5%
Total Count 33 86 71 8 198
Expected Count 33.0 86.0 71.0 8.0 198.0
%> within AU Group 16.7% 43.4%, 35.9%, 4.0 % 100.0%,
%> within Age Group 100.0%. 100.0% 100.0%, 100.0%, 100.0%
%> within Total 16.7% 43.4% 35.9% 4.0%, 100.0%,
Note: A Pearson Chi-Square value of10,69, df value of 3, p value of .01, and a Pearson R t 
value of -2.89 was found when this data was analyzed.
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Of those with a BMI over 30 kg/m2, 48.3% (n=83) used alcohol. In those with a 
BMI under 30 kg/m2, 53.3% (n=8) used alcohol. Over half, 58.8% (n=40), of those with 
a blood pressure over 130/85 mmHg used alcohol, whereas 42.2% (n=54) of those who 
had a blood pressure under this level used alcohol. Among those with a diagnosis of 
hypertension, 45.2% (n=52) drank alcohol, whereas among those in the sample who did 
not have the diagnosis 54.8% (n=63) drank (Table 45). Among those diagnosed with 
diabetes, 42.9% (n=33) used alcohol, whereas among those without the diagnosis 50.4% 
(n=61) used alcohol.
Table 46. Alcohol Use among Those with a Diagnosis of Hypertension
Hypertension Dx Now
No Yes Total
Alcohol No Count 36 63 99
Use Expected Count 38.8 60.2 99.0
% within Alcohol Use 36.4% 63.6% 100.0%
% within Hypertension 
Dx Now 48.6% 54.8% 52.4%
% of Total 19.0% 33.3% 52.4%
Yes Count 38 52 90
Expected Count 35.2 54.8 90.0
% within Alcohol Use 42.2% 57.8% 100.0%
% within Hypertension 
Dx Now 51.4% 45.2% 47.6%
% of Total 20.1% 27.5% 47.6%
Total Count 74 115 189
Expected Count 74.0 115.0 189.0
% within Alcohol Use 39.2% 60.8% 100.0%
% within Hypertension 
Dx Now 100.0% 100.0% 100.0%
% of Total 39.2% 60.8% 100.0%
Note: A Pearson Chi-Square value of,68, df value of 1, jd value of .41, and a Pearson R t 
value o f-.82 was found when this data was analyzed.
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Smoking
As seen in Table 46, a total of 56 people in the study smoked. Of these 23 were 
women and 33 were men. The percentage of women in the study who smoked was 
22.8%, while the percentage of men was 32.7%. Of those who smoked, the largest 
percentage 48.2% (n=27) fell in the 41 to 60 age group, while the largest percentage 
according to age group was 54.5% (n=18) in the 20 to 40 age group. Among the women 
this was also the case, with the largest number (n=9) in the 41 to 60 age group, but the 
largest percentage (40.0%) according to age group in the 20 to 40 age group. For men, 
the same pattern was evident, with the largest number, 18, in the 41 to 60 age group but 
the highest percent according to age group, 76.9%, in the 20 to 40 age group.
Table 47. Age Group of those Smoking and Nonsmokers









No Count 15 59 60 8 142
Expected Count 23.7 61.7 50.9 5.7 142.0
% within Smoking Group 10.6 % 41.5% 42.3% 5.6% 100.0%
% within Age Group 45.5% 68.6% 84.5% 100.0% 71.7%
% within Total 7.6% 29.8% 30.3% 4.0% 71.7%
Yes Count 18 27 11 0 56
Expected Count 9.3 24.3 20.1 2.3 56.0
% within Smoking Group 32.1% 48.2% 19.6% .0% 100.0%
% within Age Group 54.5% 31.4% 15.5% .0% 28.3%
% within Total 9.1% 13.6% 5.6% .0% 28.3%
Total Count 33 86 71 8 198
Expected Count 33.0 86.0 71.0 8.0 198.0
% within Smoking Group 16.7% 43.4% 35.9% 4.0 % 100.0%
% within Age Group 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 16.7% 43.4% 35.9% 4.0% 100.0%
Note: A Pearson Chi-Square value of20,51, df value of 3, £ value of .00, and a Pearson R t 
value o f-4.72 was found when this data was analyzed.
Approximately half, 35.3% (n=24), of those with a blood pressure over 130/85
mmHg smoked. Among those with a blood pressure under this level, 25.0% (n=32)
smoked. Just over half, 51.9% (n=27), of those who smoked had a diagnosis of
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hypertension (Table 47). Among those without the diagnosis of hypertension, 25 smoked 
compared to 48 who did not.
Of the 76 diagnosed with diabetes, 27.6% (n=21) smoked. Of those without 
diabetes, 28.7% (n=35) smoked. Among the 15 women who smoked, the vast majority, 
80.0% (n=12), also had an HDL level under 40 mg/dL. Of the females who did not 
smoke, 63.4% (n=26), had a HDL level under 40 mg/dL. Looking at males who smoked, 
the percentages were higher, at 93.3% (n=14) for those who also had an HDL level under 
50 mg/dL. Among those males who did not smoke, 87.8% (n=36) had an HDL reading 
under this level. Of the 15 with a glucose level over 200 mg/dL, 53.3% (n=8) smoked; of 
the 155 with lower glucose levels, 25.2% (n=39) smoked.
Table 48. Number who Smokes Among those With a Diagnosis of Hypertension
Hypertension Diagnosis
No Yes Total
Smoker No Count 48 90 138
Expected Count 53.0 85.0 138.0
% within Smoker 34.8% 65.2% 100.0%
% within Hypertension 
Dx 65.8% 76.9% 72.6%
% of Total 25.3% 47.4% 72.6%
Yes Count 25 27 52
Expected Count 20.0 32.0 52.0
% within Smoker 48.1% 51.9% 100.0%
% within Hypertension 
Dx 34.2% 23.1% 27.4%
% of Total 13.2% 14.2% 27.4%
Total Count 73 117 190
Expected Count 73.0 117.0 190.0
% within Smoker 38.4% 61.6% 100.0%
% within Hypertension 
Dx 100.0% 100.0% 100.0%
% of Total 38.4% 61.6% 100.0%
Note: A Pearson Chi-Square value of 2.82, df value of 1, g value of .09, and a Pearson R t 
value o f-1.68 was found when this data was analyzed.
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Altogether, there were 50 patients who smoked and had a BMI over 30 kg/m2 
compared to a total of 124 who had a BMI over 30 kg/m2 and did not smoke. Among 
those with a BMI under 30 kg/m2, 20.0% (n=3) smoked. There were 8 patients who had 
a triglyceride level over 150 mg/dL and also smoked (Table 48). These 8 made up 53.3% 
of those who smoked. Among those with a lower triglyceride level, 25.0% (n=7) 
smoked.
Table 49. Number with a Triglyceride Level Above and Below 150 mg/dL who Smoked
Smoker
No Yes Total
Q1 Triglycerides Normal (0 to 149mg/dl) Count 21 7 28
Expected Count 20.4 7.6 28.0
% within Q1 Triglycerides 75.0% 25.0% 100.0%
% within Smoker 52.5% 46.7% 50.9%
% of Total 38.2% 12.7% 50.9%
Elevated (150 or more Count 19 8 27
m9/dl) Expected Count 19.6 7.4 27.0
% within Q1 Triglycerides 70.4% 29.6% 100.0%
% within Smoker 47.5% 53.3% 49.1%
% of Total 34.5% 14.5% 49.1%
Total Count 40 15 55
Expected Count 40.0 15.0 55.0
% within Q1 Triglycerides 72.7% 27.3% 100.0%
% within Smoker 100.0% 100.0% 100.0%
% of Total 72.7% 27.3% 100.0%
Note: A Pearson Chi-Square value of .15, df value of 1, g value of .70, and a Pearson R t 
value of .38 was found when this data was analyzed.
Grouping of the Risk Factors
As shown in the Table 49, there were a total of 42 patients, 20 females and 22 
males with three or more risk factors for the MS. According to percentages this translates 
to 20.8% of the sample having the MS. There were many, 148, or 73.7% of the sample, 
with just one or two risk factors who are thus at high risk of developing the MS (Figure
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1). Of the 42 who fit into the definition of the MS, 13 had four risk factors and five had 
five risk factors, putting them at even greater risk of cardiovascular disease and diabetes.
Breaking the information down into age groups, we see those in the 20 to 40 age 
group have mainly one (42.9%) or two (31.4%) risk factors (Table 50). In the 41 to 60 
age group the largest percentage (39.1%) falls in the category of two risk factors. Those 
with one risk factor make up the second largest group with 36.8% of the total in the age 
bracket. Those in the 61 to 80 and 81 to 100 age groups also have the largest 
percentages, 37.5% and 50.0%, respectively, in the two risk factor category.
Looking at males and females separately, in terms of the age groups and number 
of risk factors, we see that the majority of females have one risk factor, whereas the 
majority of males have two. In the age 20 to 40 age group, the highest percentage, 54.5% 
(n=12), of females has one risk factor while males in this age group have the highest 
percentage (38.5%, n=5) in the two risk factors group. Among those in the 41 to 60 age 
group, the highest percentage, 43.2% (n=16), of females has one risk factor, while the 
highest percentage, 40.0% (n=20) of males has two risk factors. In the next age group, 
age 61 to 80, the largest percentage of females, 36.8% (n=14), has one risk factor, while 
the largest percentage of males, 47.1% (n=16), in the age group has two risk factors. 
Among the oldest group, age 81 to 100, the largest percentage, 50.0% (n=2), of females 
has four risk factors while the largest percentage, 75.0% (n=3), of males in the age group 
has two risk factors.
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Table 50. Comparison of the Number of Risk Factors for the Metabolic Syndrome among 
Males and Females
Number of Risk Factors Female Male Total
0 Count 7 5 12
% within Risk Factor 58.3% 41.7% 100.0%
% within Gender 6.9 % 5.0% 5.9%
% within Total 3.5% 2.5% 5.9%
1 Count 42 30 72
% within Risk Factor 58.3% 41.7% 100.0%
% within Gender 41.6% 29.7% 35.6%
% within Total 20.8% 14.9% 35.6%
2 Count 32 44 76
% within Risk Factor 42.1% 57.9% 100.0%
% within Gender 31.7% 43.6% 37.6%
% within Total 15.8% 21.8% 37.6%
3 Count 12 12 24
% within Risk Factor 50.0% 50.0% 100.0
% within Gender 11.9% 11.9% 11.9%
% within Total 5.9% 5.9% 11.9%
4 Count 4 9 13
% within Risk Factor 30.8% 69.2% 100.0%
% within Gender 4.0% 8.9% 6.4%
% within Total 2.0% 4.5% 6.4%
5 Count 4 1 5
% within Risk Factor 80.0% 20.0% 100.0%
% within Gender 4.0% 1.0% 2.5%
% within Total 2.0% .5% 2.5%
Total Count 101 101 202
% within Risk Factor 50.0% 50.0% 100.0%
% within Gender 100.0% 100.0% 100.0%
% within Total 50.0% 50.0% 100.0%
Note: A Pearson Chi-Square value of 7.95, df value of 5, jd value of .16, and a Pearson R t value of 1.57 was 
found when this data was analyzed.
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Number of Risk Factors
Figure 1. Frequency of the Five Risk Factors for the Metabolic Syndrome
Conclusion
The sample studied was made up of 202 individuals who were examined in terms 
of the five risk factors for the MS and the treatment and preventative methods used to 
address their risk factors. Looking at the first of these risk factors it was found that 118, 
or 58.4% of the sample, had a diagnosis of hypertension, while 33.7% (n=68) had a blood 
pressure reading over 130/85 mmHg. Among those with a diagnosis of hypertension, the 
majority, 44.9%, were in the 61 to 80 age group while the majority, 57.4%, of those with 
a blood pressure over 130/85 mmHg were in the 41 to 60 age group. Of the 173 patients 
in the sample who had random glucose readings in their chart, 16, six females and 10 
males, had levels over 200 mg/dL. There were 78 patients, 43 males and 35 females, or 
38.6% of the sample, who had diabetes. Altogether, 88 men and 88 women had a BMI 
over 30 kg/m2 with the mean BMI of the sample being 38.1 kg/m2 (SD=7.6).
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Table 51. Number of Risk Factors According to Age Group
Number of Risk Factors Age 20-40 Age 41-60 Age 61-80 Age SI- 
100
Total
0 Count 4 5 3 0 12
Expected Count 2.1 5.2 4.3 .5 12.0
% within Risk Factor 33.3 % 41.7% 25.0% .0% 100.0%
% within Age Group 11.4% 5.7% 4.2% .0% 5.9%
% within Total 2.0% 2.5% 1.5% .0% 5.9%
1 Count 15 32 25 0 72
Expected Count 12.5 31.0 25.7 2.9 72.0
% within Risk Factor 20.8% 44.4% 34.7% .0% 100.0%
% within Age Group 42.9% 36.8% 34.7% .0% 35.6%
% within Total 7.4% 15.8% 12.4% .0% 35.6%
2 Count 11 34 27 4 76
Expected Count 13.2 32.7 27.1 3.0 76.0
% within Risk Factor 14.5% 44.7% 35.5% 5.3% 100.0%
% within Age Group 31.4% 39.1% 37.5% 50.0% 37.6%
% within Total 5.4% 16.8% 13.4% 2.0% 37.6%
3 Count 4 9 9 2 24
Expected Count 4.2 10.3 8.6 1.0 24.0
% within Risk Factor 16.7% 37.5% 37.5% 8.3% 100.0%
% within Age Group 11.4% 10.3% 12.5% 25.0% 11.9%
% within Total 2.0% 4.5% 4.5% 1.0% 11.9%
4 Count 1 4 6 2 13
Expected Count 2.3 5.6 4.6 .5 13.0
% within Risk Factor 7.7% 30.8% 46.2% 15.4% 100.0%
% within Age Group 2.9% 4.6% 8.3% 25.0% 6.4%
% within Total .5% 2.0% 3.0% 1.0% 6.4%
5 Count 0 3 2 0 5
Expected Count .9 2.2 1.8 .2 5.0
% within Risk Factor .0% 60.0% 40.0% .0% 100.0%
% within Age Group .0% 3.4% 2.8% .0% 2.5%
% within Total .0% 1.5% 1.0% .0% 2.5%
Total Count 15 87 72 8 202
Expected Count 15.0 87.0 72.0 8.0 202.0
% within Total Meds 88.2% 43.1% 35.6% 4.0% 100.0%
% within HDL Group 100.0% 100.0% 100.0% 100.0% 100.0%
% within Total 88.2% 43.1% 35.6% 4.0% 100.0%
Note: A Pearson Chi-Square value of 15.41, df value of 15, p value of .42, and a Pearson R t value of 
2.78 was found when this data was analyzed.
The majority, 43.8%, of those with a BMI over 30 kg/m2 were in the 41 to 60 age 
group. Over half, 50.9%, of the sample with triglyceride readings had a level over 150 
mg/dL. The mean triglyceride level was 206.4 mg/dL (SD=136.3). The majority of the 
11 females and 16 males with readings over 150 mg/dL were between the ages of 61 and
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80. There were 12 females, out of a total of 21 with an HDL level recorded, who had an 
HDL level under 40 mg/dL, and 32 males, out of 35 with an HDL level recorded, who 
had a level under 50 mg/dL. The mean HDL level was 33.9 mg/dL (SD=12.3). The 
majority of those with low HDL readings were in the 61 to 80 age group and most had a 
level between 26 and 30 mg/dL. Of the prevention and treatment measures studied, 
several, such as the referrals for eye exams and to a dietician, were very rarely used. Of 
those seen more often, foot examinations or referrals thereof, were seen in 55 charts, for 
30 males and 25 females. Those between the age of 41 and 60 were most likely to have a 
foot examination or referral made, and among those with diabetes 34.6% had an exam 
completed. Of the medications or type of medication on which information was 
collected, four, aspirin, diuretics, and statins, were used by approximately one third of 
patients. ACE inhibitors were being taken by just under a fifth of the patients. Among 
those taking these five medications, the majority were between the ages of 61 and 80, 
although the majority of men on aspirin were younger, between the age of 41 and 60. 
There were 130 patients, 67 males and 63 females, in the sample that had a record of an 





The purpose of this study was to examine the prevalence of the risk factors, 
preventative and treatment measures for the metabolic syndrome (MS) in a Midwestern 
North American population. A non-experimental secondary data analysis comparative 
survey design approach was used through a chart review of 101 male patient charts and 
101 female patient charts. In chapter IV a number of differences were found between the 
males and females in the sample and between the age groups in terms of risk factors and 
preventative and treatment measures used. In this chapter the conclusions drawn from 
the study, and implications for nursing theory, clinical practice, education, as well as 
research will be examined.
High Fasting Glucose
One of the benefits of identifying those with the MS is the high likelihood of then 
also finding those with insulin resistance who are at risk of going on to develop diabetes 
and the metabolic abnormalities of dyslipidemia, prothrombotic state, inflammation, and 
oxidative stress that may then lead to vascular disease (Sorrentino, 2005). Besides these 
abnormalities, polycystic ovary disease and nonalcoholic fatty liver disease can result 
(Coopan, 2005).
Although insulin resistance often occurs together with the other risk factors for 
the MS, in some cases this may not occur. In certain populations, such as among South
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Asians, even those who are not overweight are predisposed to Type two diabetes (Paul & 
Smith, 2005). Among the Midwestern population in this study, all but two of the 16 with 
a random blood sugar over or equal to 200 mg/dL had a BMI over 30 kg/m2. In this 
study, 9.2% of the sample with glucose readings were found to have a random blood 
sugar over or equal to 200 mg/dL, compared to the 25% of U.S. adults with insulin 
resistance (Kutschman & Hadley, 2004). The difference in percentages here may be due 
to differences in how insulin resistance was measured or to the population studied. In 
this sample, 38% were already diagnosed with diabetes and receiving treatment for this. 
Of those with the MS, 76.8% had diabetes and among the 78 with diabetes, 78.2% (n=61) 
had the MS. This finding is reflected the literature, where 70 to 90% of those diagnosed 
with diabetes were found to have the MS (Coopan, 2005). Having diabetes as well as the 
MS increases the cardiovascular risk to a greater extent than either would separately 
(Liberopoulos, Mikhalidis, & Elisaf, 2005).
The study results on the prevalence of diabetes among men and women also was 
reflected in the literature with a higher rate, 42.6% versus 34.6% among men. The 
national rates, for those 20 years and older, are lower, with 10.5% of men and 8.8% of 
women having diabetes (Publications and Products, 2005). Reasons for the discrepancy 
here are most likely due to the sample used in this study not reflecting the general 
population as all had been diagnosed with obesity and many were also experiencing 
chronic conditions such as hypertension.
Hypertension
Over half of the sample, 58.4%, were found to have a diagnosis of hypertension, 
while 34.7% had readings over 130/85 mmHg. Both of these percentages are higher than
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the 24% national incidence of hypertension (Kutschman & Hadley, 2004). Again reasons 
for higher percentages in this study are most likely due to the sample having been 
diagnosed with obesity and, therefore, not representative of the general population. In 
this study, 40.8% of those with hypertension or a blood pressure over 130/85 mmHg, 
were found to have diabetes compared to the close to 50% reported in the literature as 
having hypertension and insulin resistance (Florez, Silva, Fernandez, Ryder, Sulbaran, 
Campos, Calmon, Clavel, Castillo-Florez, & Goldberg, 2005). With a lack of fasting 
blood sugar levels found a more accurate comparison here was not possible. In contrast 
to the literature showing women tending to have higher rates of hypertension than men 
among those with type two diabetes, the percentages of women and men with diabetes 
and hypertension were similar in this study, with 67.4% of men and 65.7% of women 
being diagnosed with both conditions (Relimpio, Marinez-Brocca, Leal-Cerro, Losada, 
Mangas, Pumar, & Asorga, 2004). Among the general population women also have been 
found to have higher rates of hypertension than men with percentages of 29.0% and 
27.8% respectively (Centers for Disease Control, 2005). In this study 59.4% of the 
women compared to 57.4% of the men had a diagnosis of hypertension. Here we see the 
difference in percentages remained similar but the total percent almost doubled in the 
sample studied. It is unclear how greatly the impact of a diagnosis of obesity had in 
increasing these percentages.
Raised Plasma Triglycerides
Of the five risk factors for the MS, elevated triglyceride levels has been found, in 
a study by Ninomiya, L’ltalien, Criqui, Whyte, Gamst, Chen (2003), to have the strongest 
relationship with the MS. In this study among the Midwestern population there was also
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a high percentage of those with and without the diagnosis of the MS having high 
triglyceride levels. Altogether 48.5% of men and 50% of the women with triglyceride 
readings had levels over 150 mg/dL. Males had higher levels than the females, with 
24.2% of males tested compared to just 4.5% of females tested, having levels over 350 
mg/dL. A 100.0% of those with the MS had triglyceride levels over 150 mg/dL 
compared to 74% seen in the literature (Jacobson, Case, Roberts, Buckley, Murtaugh, 
Sund, Gause, Varas, & Ballantyne, 2004). The higher rate may be due to the lower 
numbers tested and the likelihood that many of those tested may have already been 
known to have dyslipedemia.
Low High Density Lipoprotein Cholesterol
Low HDL levels are one of the most common the MS risk factors seen with 20% 
of women and 33% of men in the U.S. having levels under 1.03 mmol/1 (40 mg/dL) 
(Jacobson, Case, Roberts, Buckley, Murtaugh, Sund, Gause, Varas, Ballantyne, 2004).
In this study, 57.1% of the women and 76.4% of the men with HDL readings were found 
to have levels under 40 mg/dL. As for elevated triglyceride levels, the higher levels seen 
here are likely due to the readings available being taken on those with a history of 
dyslipedemia or risk factors for lower levels.
A study in Venezuela found those in the younger age groups tended to have lower 
HDL levels (Florez, Silva, Fernandez, Ryder, Sulbaran, Campos, Calmon, Clavel, 
Castillo-Florez, Goldberg, 2005). All of those in this study under age 40 with HDL 
readings available had readings under 31 mg/dL, while those over 30 had a third or more 
of their readings above 40 mg/dL. The study by Florez et al. (2005) also found the most 
common risk factors among those with the MS to be low HDL cholesterol (65.3%), high
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abdominal obesity (42.9%), and hypertension (38.1%). In this study, BMI levels, 
diabetes and HDL levels were the three most common risk factors. HDL levels were low 
in 72.0% of those with the MS, and those in the sample had a BMI of over or equal to 30 
and the MS in 97.5% of the cases. Diabetes occurred in 74.4%, hypertension was present 
in 70.7%, and elevated triglyceride levels in 5 9 .2 %  of those with the MS. Here again the 
higher percentages most likely reflected the skewed sample.
Body Mass Index
In the U.S, the number of people who are obese has doubled in the last decade, 
increasing from 15% to 30% (Kip, Marroquin, Kelley, Johnson, Kelsey, Shaw, Rogers, & 
Reis, 2004). This has led to multiple health problems including insulin resistance and 
subclinical inflammation as a result of the hormones and adipokines released from 
adipocytes (Cooppan, 2005; Pershadsingh, 2006). In this study, 86.7% of the sample was 
found to be obese (having a BMI over 29.9 kg/m2), while 89.9% of those with the MS 
were found to also have diabetes. Women were found to have a mean BMI of 39.0 kg/m2 
(SD=0.8), while men had a mean BMI of 37.1 kg/m2 (SD=7.0). National averages in the 
U.S., according to the National Health and Nutrition Examination Survey (Centers for 
Disease Control and Prevention, 2003), were 26.6 kg/m2 for men and 26.5 kg/m2 for 
women. Although the majority with the MS in this study also had a BMI over 30 kg/m2, 
2.5% had BMI levels below this number. In the literature one-third of those who are 
overweight or obese are found to have the MS (Liberopoulos, Mikhailidis, & Elisal, 
2005). As seen with those having diabetes, those with the MS may not be overweight 
(Kip, Marroquin, Kelley, Johnson, Kelsey, Shaw, Rogers, & Reis, 2004; Paul & Smith, 
2005; Liberopoulos, Mikhailidis, & Elisal, 2005). The differences between this study and
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the findings seen in the literature were expected as the sample was comprised of those 
who had had a diagnosis of obesity made in the past.
The prevalence of the MS has been found to increase greatly with higher BMI 
levels. Sarti and Gallagher (2006) report that with each 5% in weight gain from age 20 to 
age 53 the risk of developing the MS increases by 20%. Among the women in this study 
this increase was not found. Among those with a BMI of 21 kg/m to 30 kg/m , 85.7% 
had the MS, 38.8% of those with a BMI of 31 kg/m2 to 40 kg/m2 had the MS, 39.4% of 
those with a BMI of 41 kg/m2 to 50 kg/m2 had the MS, and 25.0% of those with a BMI of 
51 kg/m to 60 kg/m had MS. The results for the men in this study were similar to those 
in the literature, with rates increasing as the BMI increased. Those with a BMI of 21 
kg/m2 to 30 kg/m2, 31 kg/m2 to 40 kg/m2, 41 kg/m2 to 50 kg/m2, 51 kg/m2 to 60 kg/m2, 
and over 60 kg/m2 had percentage levels of the MS at 26.7%, 54.1%, 50.0%, 66.7%, and 
100.0% respectively. The unexpected results for the women may have been due to 
missing information on each risk factor in each chart, leading to no diagnosis of the MS, 
when they may have had the condition.
Preventative Measures & Treatment Recommendations
This study found 20.8% (n=42) of those in the sample had the MS compared to 
the national rate among adults of 22% (Kutschman & Hadley, 2004). The lower 
percentage is likely due to the lack of data available in many of the charts concerning the 
five risk factors. In most cases primary prevention with lifestyle changes are the first line 
of treatment with those who are at risk of developing the MS or who have been diagnosed 
with the condition (Appel, 2005; Godfrey, 2005; Jacobson et al., 2004; Linfeldt et al., 
2003; Novak, et al., 2003). To reduce an elevated blood pressure, weight control,
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increased physical activity, alcohol moderation, smoking cessation and dietary changes to 
reduce fat, sodium intake and increase fruit, vegetable and low fat dairy product intake is 
recommended (Appel, 2005; Meydani, 2005). A randomized placebo controlled study 
found those with the intervention of intensive lifestyle changes had the greatest effect in 
preventing the MS compared to those with standard lifestyle changes or standard lifestyle 
changes, along with treatment with metformin (Sigal, 2005). Those with impaired 
glucose tolerance can also be started on other thiazolidinediones, such as Glucophage 
XR, to decreases the risk of developing type 2 diabetes (Appel, 2005). Unfortunately, 
referrals for counseling or assessment on diet and exercise were rarely seen in this study. 
Altogether, there were just three referrals (two of the three had the MS) to meet with a 
dietician, three nutrition assessments (none with the MS), and no exercise counseling on 
record. Some of the reasons for these low numbers may be the advanced condition of the 
patients being seen and a failure to document the interventions. Many of the patients may 
already have attempted lifestyle changes and so had previously received the assessment 
and counseling on this.
In this study, 93.9% of those with the MS were on Aspirin, an 
antihypertensive, antidiabetic, or lipid-regulating medication. This is significantly higher 
than the 60% found among those with the MS in the general population (Jacobson et al., 
2004). Because the sample was chosen from a population that is not representative of the 
general population, this difference was not surprising. For those with low HDL levels, 
statins and fibrates are the drugs of choice if lifestyle changes have not been successful. 
Statins have been shown to help control lipid levels and also slow the atherosclerotic 
process at the endothelial level, thus reducing the risk of coronary heart disease
83
(Sarti & Gallagher, 2006). According to the National Cholesterol Education Program 
guidelines, low density lipoprotein levels should be treated before targeting the HDL 
cholesterol (Appel, 2005). In this study, there were 40 women with HDL levels under 40 
mg/dL and 50 men with levels under 50 mg/dL. There were also 31 females and 36 
males on a statin and 3 females and one male on a fibrate. Other drugs to reduce lipid 
levels included niacin and fish oil, which were each used by two patients, and nicotinic 
acid, which was not found to be used by any of those included in the sample. When 
determining what treatment to use for the MS, Godfrey (2005) and Sorrentino (2005) 
recommend the use of the Framingham scoring system, which allows one to determine 
the 10 year coronary artery disease risk of a given patient. It helps to distinguish those in 
a low-intermediate and high-intermediate and focusing treatment accordingly. The ATP 
III guidelines also include primary interventions that may be used.
For those with hypertension the goal is to initially bring the blood pressure 
reading below 130/80 mmHg. Bringing levels down to the normal range has been found 
to prevent 28.1% of coronary heart disease events in men and 12.5% of events in women 
(Wong, Pio, Franklin, L’ltalien, Kamath & Williams, 2003). Controlling blood pressure, 
HDL levels, and LDL levels within normal was found to prevent 51.3% of coronary heart 
disease events among men and 42.6% of events among women (Wong et al., 2003). If 
lifestyle changes are not effective in reaching this goal, long-acting doses of an 
antihypertensive given once daily is recommended in order to reduce side effects and 
increase adherence (Kutschman & Hadley, 2004). Although no particular 
antihypertensive has been found to be more effective in those with the MS, ACE 
inhibitors are often used as first line therapy for those with the MS and type 2 diabetes or
84
chronic kidney disease (Appel, 2005; Godfrey, 2005). In this study there were 34.7% 
with blood pressure reading equal to or above 130/85 mmHg, and there were 131 patients 
on one or more antihypertensive agent. There were also 42 males and 38 females taking 
aspirin. Aspirin, or clopidogrel if aspirin is contraindicated, is recommended for those 
with the MS as the syndrome may increase abnormal clotting (Appel, 2005). Care needs 
to be taken when prescribing antihypertensives and certain other medications, since side 
effects may worsen other risk factors for the MS. Thiazide diuretics, for example, have 
been found to have a negative impact on insulin resistance (Godfrey, 2005).
Smoking and alcohol use has been found to be adversely related to hypertension 
(Kutschman & Hadley, 2004). These factors along with a lack of physical activity, 
atherogenic diet, elevated LDL cholesterol, family history of early coronary artery 
disease, and aging have all been found to also contribute to the MS (Paul & Smith, 2005). 
This study found 73.2% of those who smoked had hypertension and/or a blood pressure 
reading over or equal to 130/85 mmHg. Of those who drank alcohol, 80.9% had a 
diagnosis of hypertension and/or a blood pressure reading over or equal to 130/85 mmHg. 
Smoking, diabetes and obesity have also been found to be independent predictors of 
systemic oxidative stress contributing to atherosclerosis through the modification of LDL 
to promote inflammatory responses and endothelial changes (Sarti & Gallagher, 2006).
Contributions to Theory, Clinical Practice/Policy, Education, & Research
Theory
Just 5.9% of those in the study were found to have no risk factors for the MS. A 
large percent of the sample had one or two risk factors. As Pender’s Health Promotion 
Model stresses, health promotion can make the difference both for those with one or two
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risk factors and for those with the MS (Pender, Murdaugh, & Parsons, 2002). If realistic 
interventions are set with the patient, many will be able to prevent or reverse the severity 
of their risk factors or eliminate them altogether. As Pender points out, lifestyle changes 
include increased physical activity and dietary changes. Changing policies to provide 
more nutritious meals in cafeterias and vending machines and directing clients to 
websites that have current and practical information on how to do this is key. Nursing 
can be involved in this way as well as through taking the opportunity to discuss diet and 
exercise with clients on each client visit. Through the development of theory which 
guides nursing practice to focus on disease prevention nurses can aide in reversing the 
trend towards higher levels of MS.
Clinical Practice/Policy
Exercise and dietary assessments or referrals were rarely found documented as 
having been carried out. Nurses can help bridge this gap by initiating discussions on 
these topics and recommending referrals as appropriate. The field of nursing can also 
work towards changing local, state and national policies in hospitals, clinics, schools and 
the community in general to promote exercise and healthy eating habits. Some of these 
changes may include eliminating junk food in vending machines in health care facilities 
or calling patients who are committed to exercise and dietary changes weekly to discuss 
how they are doing in terms of their exercise and dietary goals. Working toward policies 
that would mandate insurance companies and workplaces to encourage and pay for a 
greater number of preventative health practices may also prevent many from developing 
the MS. With growing numbers of individuals diagnosed with the MS, it is crucial that 
nurses seek to be informed on current information on the MS so that they can be a
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resource to patients and other health care providers. Interventions can then be discussed 
with the client and the nurse can be involved in reinforcing the need for lifestyle changes 
and follow up.
Education
As the MS becomes more widespread, it will become increasingly important for 
nurses to become aware of the risk factors making up the MS as well as the health 
consequences of the condition. Primary prevention techniques need to be discussed with 
practical ways of working with patients to prevent the MS. Classes on nutrition and 
exercise techniques, not always a part of nursing programs, is something that would 
prepare nurses to be better equipped to care for patients once they begin their career. 
Stressing the importance of nurses to be politically involved through, for example, 
supporting policy changes that will foster changes in the community promoting exercise 
and healthy diets is also critical.
Research
Further research in this Midwestern community to determine the exact numbers 
with the MS is needed. Repeating the study with patients who had a record of each of 
these five risk factors would be beneficial. It would also be helpful to determine the 
exact time when they were found to have these risk factors and what kinds of treatments 
were implemented. Research is also needed to identify what types of primary prevention 
techniques are being used and to what extent patients and providers are aware of the MS 
and how to prevent it. Studies on the prevalence of the MS in the younger population, 
among those under the age of 21, is also needed to determine what interventions are most 
effective for this group.
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Appendix A
Metabolic Syndrome Risk Factor Assessment Chart
Date o f  O besity diagnosis:
DOB(<1984): / / Treatm ent for Obesity: D iet Only
Gender: M ale M edication
Fem ale Surgery






Blood Sugar (mg/dl) 
Creatinine (mg/dl)
Prescribed: Yes

















M etform in 9





M icroalbum in (mg/day)
FBS/BS (mg/dl)
Liver Function ALT (U/L)





















Sibutramine 9 9 9
Orlistat 9 9 9
Rosiglitazone 9 9 9




Referred: Yes No Refused
D ietician 9 9 9
Eye Exam 9 9 9
Foot Exam 9 9 9
Provided/Assessed: Yes No Refused
N utrition/D iet A ssessm ent 9 9 9
Exercise Counseling 9 9 9
D iabetes Education 9 9 9
Electrocardiogram 9 9 9
Currently Sm oking 9 9 9
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